Videos
Browse videos by topic
All Videos
Showing 481-504 of 771 videos
Bayer shares how they are preparing for EU CTR
Veeva Systems Inc
/@VeevaSystems
Mar 28, 2022
This video provides an in-depth exploration of how Bayer, a major pharmaceutical company, is preparing for and implementing the European Union Clinical Trials Regulation (EU CTR). The presentation, led by Julian, outlines the multi-fold implications of the regulation, extending beyond just the submission process to impact various teams such as regulatory affairs, pharmacovigilance, clinical operations, and trial transparency. It highlights the strict scope of the regulation, applying only to interventional clinical trials on medicinal products for human use, and details the significant changes required in document modification, content, and the overall submission strategy. Bayer's approach involves a complete overhaul of their submission process, including the introduction of a new, dedicated role: the CTIS administrator. This role is crucial for managing interactions with the Clinical Trial Information System (CTIS), especially given the manual nature of data entry due to the absence of an API. The company is heavily leveraging Veeva solutions, specifically Veeva Vault Clinical (internally named "Gemstone") and Veeva RIM (internally named "Brave"), to centralize document management, track submissions, and facilitate rapid information flow to meet the stringent response timelines mandated by the CTR. The discussion emphasizes the shift from a local to a global submission strategy, where a central team defines submission dates and manages the complex interaction with CTIS. The presentation further details the intricate documentation and information flow envisioned under the EU CTR, with Veeva Vault Clinical serving as the central hub. It explains how various documents—from core part one documents to country-specific part two documents and safety reports—are authored, redacted, and compiled within or uploaded to Vault Clinical. Metadata is crucial for CTIS entries, and a specific strategy for Commercial Confidential Information (CCI) is in place, including deferral requests. The integration of CTMS data with Vault Clinical ensures accurate site information and study event tracking. Ultimately, the compiled submission package is manually extracted from Vault Clinical and uploaded to CTIS, with a copy of the submitted package then archived back in Vault Clinical for eTMF purposes. The reliance on Veeva RIM for tracking submission and approval dates, integrated with Vault Clinical, underscores Bayer's commitment to a unified and compliant regulatory information management system. Key Takeaways: * **Multi-faceted Impact of EU CTR:** The EU CTR is not merely a new submission process; it has profound implications across regulatory affairs, pharmacovigilance, clinical operations, and trial transparency, requiring a holistic organizational adaptation. * **Strict Scope and Timelines:** The regulation specifically targets interventional clinical trials on medicinal products in human use, introducing very strict response timelines for requests for information (RFIs), necessitating rapid internal information flow. * **Process Reversal and Centralization:** Bayer has implemented a "reversal of the process," moving from local submission packages to a global function that collects documents and data from local organizations, defines optimal submission dates, and manages CTIS interactions centrally. * **New Dedicated Role: CTIS Administrator:** A critical new role, the "CTIS administrator," has been created to interact directly with the CTIS. Their responsibilities include managing user permissions, uploading approved documents, monitoring CTIS for RFIs, distributing information internally, and tracking submission/approval dates. * **Leveraging Veeva Ecosystem:** Bayer is heavily relying on Veeva solutions, including Veeva Vault Clinical (Gemstone) for CTIS submission preparation, compilation, and eTMF, and Veeva RIM (Brave) for regulatory submission tracking and future document authoring. They also plan to replace their former CTMS with a Veeva tool. * **Manual CTIS Interaction Challenge:** A significant challenge highlighted is the lack of an API for CTIS, meaning manual data entry and document upload. This necessitates a robust internal system (like Veeva Vault Clinical) to prepare and organize information for efficient manual transfer. * **Structured Document Management for Compliance:** Bayer has modified its document classification to distinguish between protected personal data (PPD) and redacted documents ready for publication, and introduced metadata (CCI tags) to track commercial confidential information, ensuring compliance with disclosure rules. * **Veeva Vault Clinical as Central Hub:** Veeva Vault Clinical (Gemstone) serves as the central repository and compilation system for all CTIS documentation and data fields, integrating contributions from various functions and external systems. * **Comprehensive Data Flow Strategy:** The documentation flow involves authoring and publication outside Vault Clinical, site-collected documents, CCI strategy documents, safety reporting, and CTMS integration, all converging into Vault Clinical before manual upload to CTIS. * **Archiving and Tracking Post-Submission:** After submission, a copy of the CTIS submission package is downloaded and re-uploaded to Veeva Vault Clinical for archiving and eTMF purposes, ensuring a complete audit trail. * **Importance of Metadata and EDLs:** Specific metadata fields are used during document upload to mirror CTIS entry requirements, and EU CTR-specific Expected Document Lists (EDLs) are adopted for respective milestones to ensure all necessary data fields are collected. * **Strategic Planning for Submissions:** The regulation's rules on dossier modification during ongoing evaluations (e.g., Part One) necessitate a well-defined submission strategy and a clear overview of ongoing study activities, which Veeva dashboards and RIM help facilitate. Tools/Resources Mentioned: * **Veeva Vault Clinical (Gemstone):** Bayer's internal name for their Veeva Clinical Vault, used as the central system for CTIS submission preparation, compilation, document management, and eTMF. * **Veeva RIM (Brave):** Bayer's internal name for their Veeva Regulatory Information Management system, used for tracking submission and approval dates, and planned for future document authoring. * **Veeva Workflow:** Utilized to manage strict response timelines and ensure quick information flow. * **Veeva Dashboard:** Used to provide a good overview of ongoing study activities and submission needs. * **Clinical Trial Information System (CTIS):** The official EU portal for clinical trial submissions and interactions, which currently requires manual data entry. * **CTMS (Clinical Trial Management System):** Bayer plans to replace their former CTMS with a Veeva solution for managing country and site information, and study events. Key Concepts: * **EU Clinical Trials Regulation (CTR):** A regulation governing the conduct of clinical trials in the European Union, aiming to simplify and harmonize the submission and oversight processes. * **Clinical Trial Information System (CTIS):** The centralized online platform for submitting and assessing clinical trial applications in the EU under the CTR. * **Part One & Part Two:** The CTR divides the clinical trial application into two parts: Part I (scientific and medicinal product documentation) and Part II (country-specific and site-specific documentation). * **Expected Document List (EDL):** A list of documents expected for a specific regulatory submission or milestone. * **Commercial Confidential Information (CCI):** Information that is considered confidential for commercial reasons and may require deferral requests for publication under the CTR. * **Protected Personal Data (PPD):** Personal data that needs to be protected and redacted before public disclosure. * **Request for Information (RFI):** Queries or requests for additional information from regulatory authorities during the assessment of a clinical trial application. * **eTMF (Electronic Trial Master File):** An electronic system for managing and storing essential clinical trial documents.
Healthcare IT Interoperability and EMR Interoperability Explained
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Mar 27, 2022
This video provides an in-depth exploration of Electronic Medical Record (EMR) and Electronic Health Record (EHR) interoperability, focusing on the challenges and realities of sharing healthcare data between different hospital systems and doctor practices in the United States. Dr. Eric Bricker begins by establishing the context that the vast majority of health information is now stored electronically, moving away from traditional paper charts. He highlights the historical problem of data siloing, where individual healthcare providers had their own computer systems that did not communicate, leading to fragmented patient information. The presentation then delves into the widespread consensus among various stakeholders—patients, federal and state governments, insurance companies, employers, and even the American Hospital Association (AHA)—that health information *should* be shared. The stated benefits of interoperability are compelling: increased patient safety, improved care quality, enhanced ability to track public health issues like pandemics, and decreased healthcare costs. Despite this universal agreement on the desirability of data sharing, Dr. Bricker transitions to reveal the stark reality of its implementation across major U.S. cities, citing data from the federal government. The video presents specific statistics on the percentage of hospitals sharing patient data in various metropolitan areas, showcasing a wide disparity: Cleveland leads at 78%, followed by Miami (77%) and Dallas (60%), while Boston stands at 50%, and Philadelphia lags significantly at only 35%. Dr. Bricker expresses skepticism and disappointment at these low figures, questioning why such fundamental data sharing remains elusive in an advanced technological era. He then introduces a critical insight: the barriers to interoperability are not solely technological. He shares a compelling true story about a large multi-specialty physician practice (over 500 doctors) that *deliberately* stopped sharing CT images with a local hospital, despite having previously seamless, cost-free interoperability. Instead, they began charging patients to burn images onto CDs, forcing patients to physically transport them. This policy change, he notes, correlated with the practice being acquired by a private equity firm, suggesting that financial incentives and strategic patient retention (using data as leverage) can override patient-centered care and efficient data sharing. Key Takeaways: * **Definition of EMR/EHR Interoperability:** Interoperability refers to the ability of different healthcare systems and practices to seamlessly share electronic patient data, including disease history, physical exam findings, lab results, and imaging scans (CT, MRI, X-rays). * **Universal Desire for Data Sharing:** There is broad consensus across patients, federal and state governments, insurance companies, employers, and even the American Hospital Association (AHA) that health information should be shared for better healthcare coordination. * **Significant Benefits of Interoperability:** Sharing health data is crucial for increasing patient safety, improving care quality, facilitating the tracking and management of public health crises like pandemics, and ultimately decreasing overall healthcare costs. * **Low Rates of Actual Interoperability:** Despite the recognized benefits and technological capabilities, the actual rates of health information sharing among hospitals in major U.S. cities remain surprisingly low, with figures ranging from a high of 78% in Cleveland to a mere 35% in Philadelphia. * **Beyond Technological Barriers:** The primary obstacles to interoperability are often not technological limitations but rather organizational unwillingness, competitive strategies, and financial incentives that prioritize self-interest over patient care. * **Data as a Competitive Lever:** Healthcare providers, particularly large physician practices and hospital systems, may intentionally restrict data sharing to increase "patient stickiness," making it harder for patients to seek care elsewhere and reducing competition based on price and quality. * **Impact of Private Equity Ownership:** A real-world case study illustrates how a multi-specialty practice, after being acquired by a private equity firm, ceased providing direct access to patient imaging data to an affiliated hospital, instead reverting to cumbersome, patient-burdened methods like burning CDs. * **Discrepancy Between Stated and Actual Priorities:** Organizations often claim to be "patient-centered" in their marketing, but their actions, such as deliberately hindering data sharing, reveal their true priorities, which may be profit or market control. * **Inefficiency of Non-Interoperable Data Transfer:** The practice of burning medical images onto CDs for patient transport is highlighted as an outdated, clunky, and inefficient process that significantly impedes timely and effective patient care, especially in critical situations like cancer diagnosis. * **Implications for Patient Choice and Quality of Care:** The lack of interoperability can restrict patients' access to world-expert physicians or alternative care settings, as their data is held captive within specific health systems, potentially compromising optimal treatment outcomes. Key Concepts: * **EMR (Electronic Medical Record):** A digital version of a patient's chart from a single practice or hospital. * **EHR (Electronic Health Record):** A more comprehensive digital record of a patient's health information that is shareable across different healthcare settings. * **Interoperability:** The ability of different information systems, devices, and applications to access, exchange, integrate, and cooperatively use data in a coordinated manner. * **Data Siloing:** The isolation of data within individual systems or departments, preventing easy access and sharing across an organization or between different organizations. Examples/Case Studies: * **U.S. Government Interoperability Survey:** Data from the federal government (healthit.gov) on the percentage of hospitals sharing patient data in major U.S. cities, including Cleveland (78%), Miami (77%), Dallas (60%), New York City (59%), Chicago (58%), Boston (50%), Washington D.C. (44%), Los Angeles (41%), and Philadelphia (35%). * **Multi-Specialty Physician Practice Case Study:** A 500+ doctor multi-specialty practice in a major U.S. city that ceased providing direct electronic access to CT images for a local hospital, instead requiring patients to pay for and transport images on CDs, a policy change that correlated with new private equity ownership.
Top 10 Reasons to Podcast
Self-Funded
@SelfFunded
Mar 25, 2022
This video provides an in-depth exploration of the top ten reasons why individuals and businesses, particularly those in sales, should consider starting a podcast. The speaker, Spencer Smith, presents a compelling argument for podcasting as a powerful tool for business development, brand building, and lead generation, drawing from his personal experience with his "Self-Funded" podcast. He frames podcasting not merely as a content creation activity but as a strategic sales and marketing initiative that can significantly accelerate traditional business growth cycles. The presentation progresses through a structured list of ten benefits, starting with immediate brand recognition and moving through various stages of relationship building, credibility establishment, and ultimately, lead generation and content longevity. Smith emphasizes that a podcast allows the host to control the narrative, invite industry experts, and build a platform that positions them as a thought leader. He contrasts the traditional struggle to gain a "seat at the table" with the empowerment of creating one's own table, inviting high-profile guests, and shaping the discourse around relevant topics. A core theme throughout the discussion is the shift from transactional selling to value-driven engagement. Smith highlights that a podcast inherently sells value and ideas, offering free information and fostering trust without an immediate product pitch. This approach, he argues, builds rapport and credibility far more effectively and quickly than conventional sales methods. He illustrates how consistent content creation leads to a library of reusable assets that can serve as perpetual lead generation tools and follow-up resources, significantly reducing the manual effort typically required in the sales process. The speaker's perspective is highly practical and results-oriented, focusing on the tangible benefits for a salesperson or business owner. He shares anecdotal evidence from his own podcasting journey, including how listeners have approached him for demos after months of consuming his content, demonstrating the long-term, passive lead generation potential. The underlying methodology is that by consistently providing value and expertise through a podcast, one can cultivate an audience that trusts and respects them, making the eventual sales conversation much easier and more effective. Key Takeaways: * **Immediate Brand Recognition:** Podcasting offers a direct path to establishing personal or company brand recognition. By consistently producing content, individuals and organizations can become known to a target audience, fostering familiarity and recall. * **Create Your Own Platform:** Instead of seeking invitations to industry discussions, a podcast allows you to create your own "table," inviting experts and high-profile guests, thereby positioning yourself as a central figure in relevant conversations. * **Association with Expertise:** Hosting experts on your podcast allows you to associate your brand with their knowledge and credibility, enhancing your own perceived expertise even if you're not the sole subject matter expert on every topic. * **Represent Company Values:** Podcasting provides a unique medium to articulate and consistently demonstrate your company's core values, mission, and what you stand for, resonating with an audience that shares similar principles. * **Control the Conversation:** A podcast grants the host control over the topics discussed, the guests invited, and the overall flow of information, enabling strategic shaping of industry narratives and thought leadership. * **Value-Driven Selling:** Podcasting inherently focuses on providing free value, ideas, and insights rather than directly selling a product. This builds trust and positions the host as a helpful resource, making future sales conversations more natural and less transactional. * **Accelerated Rapport Building:** Regular listeners develop a sense of knowing, liking, and trusting the host over time, significantly shortening the rapport-building phase typically required in a traditional sales funnel. * **Instant Credibility:** Consistently hosting intelligent conversations and weighing in with valuable insights on a podcast establishes instant credibility, which is a powerful asset when engaging in sales discussions or attending industry events. * **Proactive and Passive Lead Generation:** Podcasting generates leads both directly (e.g., through calls to action or direct outreach to viewers) and passively (e.g., listeners reaching out after consuming content for an extended period), reducing the need for active prospecting. * **Perpetual Reusable Content:** A single podcast episode can be repurposed into multiple clips, articles, or social media posts, creating a vast library of evergreen content that can be used for lead nurturing, follow-ups, and ongoing marketing efforts in perpetuity. Key Concepts: * **Brand Recognition:** The extent to which a consumer can identify a brand by its name, logo, or other visual elements. Podcasting accelerates this by providing consistent exposure. * **Thought Leadership:** The position of being an authoritative expert in a particular field, whose expertise is sought out and whose opinions are respected. Podcasting facilitates this by allowing hosts to curate and lead discussions with other experts. * **Value-Driven Content:** Content that prioritizes providing free, useful, and insightful information to the audience, rather than directly promoting a product or service. This approach builds trust and long-term relationships. * **Sales Funnel Acceleration:** Strategies and tactics that shorten the time it takes for a prospect to move through the various stages of the sales process, from initial awareness to conversion. Podcasting achieves this through pre-built rapport and credibility. * **Content Repurposing:** The practice of taking existing content and transforming it into different formats or distributing it across various channels to maximize its reach and utility. A single podcast recording can yield numerous derivative content pieces. Examples/Case Studies: * **"Self-Funded" Podcast:** The speaker's personal podcast, which serves as a primary example of how he applies these principles to build his brand and generate leads. * **"Plan Site":** Mentioned as the speaker's company or product, indicating how his podcasting efforts directly support his business endeavors. * **"Stop-Loss Videos":** A previous content series created by the speaker, highlighting his history of creating valuable, niche-specific content to establish expertise.
IDMP in a capsule Tutorial
UNICOM
/@UNICOM-IDMP
Mar 24, 2022
This. The emphasis on patient safety and pharmacovigilance further underscores its relevance to medical affairs and regulatory compliance departments within their target market. This tutorial provides a comprehensive overview of the Identification of Medicinal Products (IDMP) standards, highlighting their crucial role in ensuring global medication safety. It explains how the ISO IDMP standards, though inconsistently implemented, are designed to work throughout a medicinal product's life cycle, from development and production to utilization and outcome assessment. Through illustrative stories, the video demonstrates how IDMP helps prevent adverse drug events, facilitates safe substitutions across different countries, curbs falsified medicines, and enhances global pharmacovigilance. A central theme is the concept of Medicinal Product Dictionaries (MPDs) as national repositories for comprehensive product information, linked globally by the Pharmaceutical Product Identifier (PHP ID), enabling seamless data navigation and personalized patient care through integration with personal health data. Key Takeaways: * **Standardized Global Identification is Critical:** Inconsistent identification of medicinal products across countries poses significant patient safety risks. IDMP provides a standardized framework (substance, dose form, strength, medicinal product, package) to ensure globally unique identification, crucial for safe healthcare and preventing errors. * **Medicinal Product Dictionaries (MPDs) as Central Data Hubs:** MPDs are vital national repositories that consolidate comprehensive product information (regulatory, scientific, pricing, dosage guidance). These dictionaries are the foundation for all information needed by hospitals, doctors, and pharmacies for safe prescribing and dispensing, and are accessed through various healthcare IT systems. * **The PHP ID Enables Cross-Border Data Linkage:** The Pharmaceutical Product Identifier (PHP ID) is a critical global identifier that allows for the seamless navigation and comparison of equivalent medicinal products across different national MPDs. This capability is essential for facilitating safe substitutions for patients traveling internationally and for aggregating global pharmacovigilance data. * **IDMP Supports Personalized Patient Safety:** By integrating IDMP-compliant product data from MPDs with individual patient health data (e.g., International Patient Summary - IPS), intelligent applications can provide real-time, personalized alerts for allergies, intolerances, and potential drug-drug interactions, significantly enhancing medication safety at the point of care. * **Enhanced Global Pharmacovigilance:** IDMP-compliant reporting, which includes the PHP ID and other identifiers, streamlines the aggregation and analysis of adverse drug event data globally. This enables faster identification of safety patterns, quicker responses (e.g., product recalls, updated warnings), and proactive risk mitigation across populations. * **Call for Industry-Wide Implementation:** The full benefits of IDMP, including improved medication safety and public health outcomes, can only be realized through widespread and consistent implementation by pharmaceutical companies, regulators, and IT solution providers across the entire medicinal product life cycle.
Self-Funded w/ Spencer - True Captive - 4/6
Self-Funded
@SelfFunded
Mar 24, 2022
This video provides an in-depth exploration of the intricacies of Pharmacy Benefit Managers (PBMs) within the self-funded employee benefits landscape, with a particular focus on the growing movement towards transparency. Featuring Rachel Strauss, Director of Strategic Development at EHIM, the discussion aims to demystify the operational models of PBMs, highlighting the critical differences between traditional and transparent approaches. The core objective is to educate employers on how PBMs generate revenue and to challenge common misconceptions, especially regarding the perceived value of drug rebates. The conversation begins by establishing the fundamental distinction between transparent and traditional PBM models. Rachel Strauss explains that the primary difference lies in how PBMs are compensated. In a traditional model, administrative fees are often obscured, with PBMs embedding their profits directly into the cost of claims, making it difficult for employers to ascertain the true cost of services. In contrast, transparent PBMs, like EHIM, operate on a clear administrative fee structure, explicitly detailing their charges to clients. This shift towards transparency is presented as a response to a broader demand for clarity in an era where PBMs frequently face scrutiny over their financial practices. A significant portion of the discussion is dedicated to dissecting the "rebate" system, which Rachel Strauss identifies as a major problem area. She argues that rebates are often viewed by employers as "free money" or a form of savings, akin to a tax return. However, she clarifies that receiving a rebate implies an initial overpayment. Spencer reinforces this by drawing an analogy to an "experience reward" or dividend contract in stop-loss insurance, where an upfront premium load is paid with the hope of a partial return later. This psychological framing, the speakers contend, tricks employers into a "sunk cost fallacy," making them believe they are saving money when they are, in fact, paying more upfront for the chance of a partial return, rather than questioning the initial expenditure. The video concludes by emphasizing the evolving landscape of employee benefits, driven by an increased demand for data and actionable insights from employers. Rachel notes that regulatory changes, such as the "No Surprises Act," are contributing to a greater openness and a push for information freedom. The overall message underscores a shift in the industry from merely identifying pain points to actively prescribing tangible solutions. The speakers highlight the importance of empowering employers to critically evaluate their spending and explore alternative, more cost-effective options, rather than passively accepting opaque models and perceived savings through rebates. Key Takeaways: * **Fundamental PBM Model Differences:** The core distinction between transparent and traditional PBMs lies in their compensation structure. Transparent PBMs charge explicit administrative fees, while traditional models often embed their profits within the cost of claims, leading to opacity. * **The Illusion of Rebates:** Rebates, often perceived as "free money" or savings by employers, are fundamentally a return of funds that were initially overpaid. This creates a misleading sense of financial benefit. * **Sunk Cost Fallacy in Benefits:** The rebate model can lead employers into a "sunk cost fallacy," where they assume they must spend a certain amount to receive a rebate, rather than questioning whether the initial expenditure was necessary or optimal. * **Analogy to Stop-Loss Experience Rewards:** The concept of rebates is compared to an "experience reward" in stop-loss contracts, where a higher upfront premium is paid for the potential of a partial return, illustrating that the "savings" come at an initial cost. * **Employer Demand for Data and Action:** There is a growing trend among employers to not only demand access to their benefits data but also to seek actionable insights and clear solutions derived from that data, moving beyond mere data availability. * **Impact of Regulatory Changes:** Legislation like the "No Surprises Act" is fostering an environment of greater transparency and information freedom within the healthcare and employee benefits sectors, pushing for more accountable practices. * **Industry Shift Towards Solutions:** The benefits industry is evolving to provide concrete solutions to identified problems, rather than just elaborating on pain points, offering employers clearer pathways to optimize their plans. * **Psychological Framing of Savings:** The way rebates are presented can psychologically train employers to believe they are saving money, even when they are effectively overpaying upfront to get a portion back later. * **Importance of Questioning Initial Spend:** Employers are encouraged to question the initial cost of their prescription drug benefits and explore whether better, more cost-effective options exist, rather than simply focusing on the rebate amount. * **Transparency as a Revolution:** The shift towards transparent PBM models is framed as a "revolution" driven by the need for employers to understand exactly what they are paying for and how their PBM is compensated. Key Concepts: * **PBM (Pharmacy Benefit Manager):** A third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, and other government and private programs. * **Transparent PBM:** A PBM model where administrative fees are clearly itemized and disclosed to the client, and all rebates and discounts are passed directly back to the client. * **Traditional PBM:** A PBM model where administrative fees may be less explicit, and the PBM may retain a portion of rebates or spread pricing, making the true cost opaque to the client. * **Rebates:** Payments from pharmaceutical manufacturers to PBMs, typically for placing their drugs on a formulary or for market share. The video discusses how these are often viewed as savings but can mask higher initial costs. * **Administrative Fees:** Explicit charges for the services provided by a PBM, distinct from the cost of the drugs themselves. * **Experience Reward (Stop-Loss):** A feature in some stop-loss insurance contracts where a portion of the premium may be returned to the policyholder if claims run below a certain threshold, analogous to rebates in PBMs. * **Sunk Cost Fallacy:** A cognitive bias where an individual continues a behavior or endeavor as a result of previously invested resources (time, money, effort), even if future costs outweigh the benefits. * **No Surprises Act:** A U.S. federal law that protects consumers from surprise medical bills, particularly those from out-of-network providers or facilities. Its mention in the video highlights a broader regulatory push for transparency in healthcare.
CTMS Oversight Deep Dive Demo
Veeva Systems Inc
/@VeevaSystems
Mar 22, 2022
This video provides a deep dive into Veeva Vault CTMS, showcasing its capabilities for comprehensive clinical trial oversight. It highlights how the platform facilitates effective collaboration, streamlines negotiations with CRO partners, and ensures regulatory compliance. The demonstration covers integrated study management, from initial planning and site activation to ongoing monitoring, risk assessment, and issue resolution. A central theme is the seamless integration between CTMS and TMF components, ensuring all clinical activities and documentation are managed within a unified, compliant system. The video also emphasizes robust data tracking, automated processes, and advanced reporting for real-time insights into study progress, site performance, and CRO oversight. Key Takeaways: * **Integrated Clinical Operations & Compliance:** Veeva Vault CTMS provides a unified platform for managing clinical trials, integrating CTMS and TMF functionalities to ensure seamless document management, regulatory compliance (e.g., 21 CFR Part 11 for signatures, automatic TMF artifact creation), and inspection readiness. * **Enhanced CRO and Vendor Oversight:** The system offers robust tools for managing and collaborating with CROs, including a global personnel directory for access control, automated notifications for CRO-submitted data (e.g., trip reports), dedicated issue logging against CROs, and dashboards for tracking vendor performance and issue resolution times.ai to offer AI-powered enhancements for predictive CRO performance, automated contract compliance checks, or intelligent issue triage. * **Proactive Risk Management & Issue Resolution:** The platform supports templatized risk assessments with automated scoring and integrated mitigation plans. It also provides comprehensive issue management capabilities, allowing for logging, assignment (including to CROs), tracking of resolution times, and trending analysis of quality findings and protocol deviations.ai could leverage AI/LLMs to enhance risk prediction, suggest optimal mitigation strategies, or automate the generation of issue summaries. * **Data-Driven Decision Making & Business Intelligence:** Extensive reporting and dashboard features provide real-time visibility into study progress, enrollment metrics, site performance, and TMF completeness. This enables data-driven decision-making, identification of at-risk milestones, and comparative analysis of CRO performance. * **Streamlined Workflow Automation:** The system automates several critical workflows, such as subject data calculation for actuals, automatic completion of milestones, generation of risk assessment documents, and creation of Part 11 compliant trip reports, significantly reducing manual effort and enhancing efficiency.
E3: xEVMPD Maintenance with Donika Doda
The Voice of Life Sciences
/@thevoiceoflifesciences1321
Mar 17, 2022
This video provides an in-depth exploration of xEVMPD (Extended Eudravigilance Medicinal Product Dictionary) maintenance, a critical regulatory compliance requirement for pharmaceutical companies operating within the European Union. Donika Doda, a Regulatory Affairs Specialist, discusses the complexities and strategies involved in making appropriate data submissions to the European Medicines Agency (EMA). The discussion highlights xEVMPD's role as the "mother of EMA databases," established in 2012 as part of Pharmacovigilance Legislation, serving as a central dictionary for medicinal product information and an interface for adverse event reporting. The conversation delves into the practicalities of xEVMPD maintenance, particularly how it fits into the post-approval phase of variation management. When a variation, such as a change to a Summary of Product Characteristics (SPC) or leaflet, is approved and impacts xEVMPD, companies are mandated to submit updated data to Eudravigilance within strict timelines (typically 15 or 30 days). Donika describes a largely manual process where Regulatory Affairs teams receive approved labeling, communicate the change, and then a designated person manually enters the database, finds the correct product, performs the update, and sends it to the EMA, awaiting an acknowledgment message. This manual process is underscored as a legal compliance obligation, crucial for ensuring healthcare professionals have access to the most current and accurate information, especially concerning safety variations. A significant portion of the discussion focuses on the challenges associated with xEVMPD maintenance. These include the inherent complexity of manual data entry, the need for precise timing, and the organizational hurdles arising from involving multiple departments like Pharmacovigilance and Regulatory Affairs. Donika emphasizes that the number of steps in the process directly impacts efficiency, advocating for streamlined workflows. A major pain point identified is the pervasive data duplication across various departmental software systems that often "do not talk to each other," leading to inefficiencies and wasted resources. This fragmentation necessitates a broader industry shift towards digital transformation. Looking to the future, the video introduces IDMP (Identification of Medicinal Products) as the "big brother" to xEVMPD, representing a significant opportunity for the industry to enhance efficiency and collaboration. IDMP is anticipated to facilitate a real interface between company software systems and the EMA, drastically reducing the time and effort required for data communication and maintenance. This upcoming standard is seen as a catalyst for companies to align their data, foster inter-departmental collaboration, and reduce duplication. The speakers advocate for companies to embrace this digital transformation, potentially by establishing dedicated teams responsible for managing this transition, ultimately leading to quicker access to reliable information for patients, healthcare professionals, and more efficient assessment processes for regulators. Key Takeaways: * **xEVMPD as a Core Regulatory Database:** The Extended Eudravigilance Medicinal Product Dictionary (xEVMPD) serves as the foundational "mother of EMA databases," centralizing medicinal product information and linking to pharmacovigilance for adverse event reporting. * **Mandatory Compliance for EU Operations:** Since 2012, xEVMPD maintenance has been a mandatory legal compliance requirement for all pharmaceutical companies with products registered in the European Union. * **Manual and Time-Sensitive Update Process:** Following the approval of variations (e.g., changes to SPC or leaflets), companies must manually update xEVMPD data within strict deadlines (15 or 30 days), involving regulatory affairs teams and direct communication with the EMA. * **Critical for Patient Safety and Healthcare Professionals:** Maintaining an up-to-date xEVMPD database is vital for patient safety, as healthcare professionals rely on this information from their respective authorities to ensure they have the latest details on prescribed or used products, especially for safety variations. * **Challenges of Inter-Departmental Complexity:** The maintenance process is complicated by involving multiple departments, such as Pharmacovigilance and Regulatory Affairs, highlighting the need for clear roles, responsibilities, and efficient communication channels. * **Inefficiencies Due to Data Duplication and Disparate Systems:** A significant challenge is the widespread duplication of information across different departmental software systems that lack interoperability, leading to wasted resources and increased effort. * **IDMP as a Catalyst for Digital Transformation:** The upcoming IDMP (Identification of Medicinal Products) standard is viewed as a major opportunity to drive digital transformation, promising a real interface between company software and the EMA, thereby reducing communication and maintenance times. * **Opportunity for Streamlined Operations and Collaboration:** IDMP implementation encourages companies to align data, foster greater collaboration between departments, and reduce data duplication, leading to more efficient internal operations. * **Need for Dedicated Digital Transformation Teams:** Companies are advised to consider establishing dedicated teams responsible for managing digital transformation initiatives to ensure a cohesive approach and successful adoption of new technologies and regulatory standards. * **Benefits of Digital Adoption:** Embracing digital transformation and implementing connectors between systems will reduce timing and effort, improve data reliability, and ultimately lead to quicker access to information for patients and healthcare professionals, as well as more efficient regulatory assessments. Key Concepts: * **xEVMPD (Extended Eudravigilance Medicinal Product Dictionary):** A mandatory EMA database containing information on all medicinal products registered in the European Union, serving as a central dictionary and linked to pharmacovigilance. * **Eudravigilance:** The European Medicines Agency's (EMA) system for managing and analyzing information on suspected adverse reactions to medicines authorized in the European Economic Area (EEA). * **EMA (European Medicines Agency):** The agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union. * **Pharmacovigilance:** The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. * **IDMP (Identification of Medicinal Products):** A set of ISO standards for the unique identification of medicinal products, aimed at standardizing the way medicines are identified and described globally. * **SPC (Summary of Product Characteristics):** A document that describes the properties and the approved conditions of use of a medicinal product. * **Leaflet:** The patient information leaflet (PIL) that comes with a medicine, providing information on how to use it safely and effectively. * **Variation Management:** The process of managing changes to a medicinal product's marketing authorization after it has been approved. Tools/Resources Mentioned: * **Eudravigilance:** The database to which xEVMPD updates are submitted. * **Vault:** Mentioned as a potential platform where connectors might be built for future integration.
Behavior Modification in Healthcare
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Mar 12, 2022
This video provides an in-depth exploration of behavior modification in healthcare, leveraging Professor BJ Fogg's renowned model. Dr. Eric Bricker, the presenter, begins by establishing the fundamental premise that improving health outcomes, quality, and reducing costs necessitates a change in human behavior. The core of the discussion revolves around applying Fogg's model—which posits that behavior change requires the simultaneous presence of Motivation, Ability, and a Trigger—to increase primary care utilization among members of employer-sponsored health plans. The presentation meticulously breaks down each component of the Fogg model, illustrating how a deficiency in any one area can prevent desired behavior change. Dr. Bricker uses a visual representation of Fogg's "action line," explaining that for difficult tasks, high motivation is required, while for easy tasks, low motivation suffices. Crucially, triggers only work when an individual is on the "right side" of this action line, meaning they possess sufficient motivation and ability. If a task is too hard or motivation is too low, triggers will fail, regardless of how frequently they are applied. Dr. Bricker then applies this framework to the real-world problem of low primary care engagement, citing statistics where only 15-50% of employees in large companies see a primary care physician within two years. He analyzes the current state, identifying that motivation is often low because the body is remarkably resilient, masking early signs of disease, and job-based incentives often fall flat due to general employee disengagement. Ability is severely hampered by the logistical difficulties of traditional primary care (time off work, travel, waiting, short doctor visits). Triggers are ineffective because they are typically generic and not personalized to individual needs, such as a 25-year-old male versus a 45-year-old female. The video concludes by outlining solutions for each component, drawing on the ancient Greek principles of persuasion (ethos, pathos, logos) for motivation, modern access solutions (on-site, virtual primary care) for ability, and personalized, multi-channel communication for triggers. The discussion culminates with a compelling case study of Serigraph, an automotive parts manufacturer that successfully kept its healthcare costs flat for nearly a decade by implementing these behavior modification strategies. Serigraph utilized a combination of monetary and time-off incentives, established an on-site clinic to drastically improve access and ease (ability), and employed "hyper-communication" through various channels, including mandated annual face-to-face coaching, to deliver highly personalized triggers. This real-world example underscores the practical applicability and profound impact of Fogg's model when systematically applied to healthcare challenges. Key Takeaways: * **BJ Fogg's Behavior Model (B=MAT):** Behavior change (B) is a product of Motivation (M), Ability (A), and a Trigger (T). All three elements must be present simultaneously for a behavior to occur. * **The "Action Line":** Fogg's model includes an "action line" on a graph where motivation (y-axis) and ability (x-axis) intersect. Behaviors above this line are more likely to occur with a trigger; those below will not, regardless of triggers. * **Motivation Challenges in Healthcare:** Individuals often lack motivation for preventative health due to the body's ability to mask disease symptoms until advanced stages. Generic job-based health incentives frequently fail to engage employees. * **Ability Barriers in Traditional Primary Care:** Accessing traditional primary care is often difficult, requiring significant time off work, travel, and waiting, making it a "half-day escapade" for a brief doctor interaction. This high effort severely limits ability. * **Ineffective Triggers:** Broad, non-personalized communication (e.g., mass emails) fails to resonate with diverse employee populations, as healthcare needs vary significantly by age, gender, and other demographics. * **Building Motivation through Persuasion:** Effective motivation for health comes from credible sources (doctors - Ethos), empathetic listening (Pathos), and then logical reasoning (Logos). Starting with logic without credibility and empathy is ineffective. * **Enhancing Ability with Accessible Care:** Making primary care "super easy" is crucial, especially for those with low motivation. Solutions include on-site clinics, near-site clinics, direct primary care, and virtual primary care, which reduce logistical barriers. * **Personalized Triggers are Essential:** Communication must be customized to the individual's needs and preferences. This can involve different channels (emails, texts, hard copies, spousal communication) and face-to-face coaching for tailored messaging. * **Triggers Fail Below the Action Line:** If motivation is low and ability is hard (below the action line), no amount of triggering (emails, texts, counseling) will result in behavior change; the foundational issues of motivation and ability must be addressed first. * **Serigraph Case Study - Integrated Approach:** The manufacturing company Serigraph successfully flattened healthcare costs for 10 years by combining incentives (monetary, time off), an on-site clinic (improving ability), and "hyper-communication" including mandated annual face-to-face coaching (personalized triggers). * **The Power of On-Site Clinics:** For concentrated workforces, on-site clinics significantly enhance ability by making care convenient, quick, and requiring no time off, which was a "crux" of Serigraph's success. * **Virtualization for Distributed Workforces:** For companies with geographically dispersed employees, virtual primary care is critical to replicate the "ease" factor of on-site clinics and overcome ability barriers. * **Conversations as Key to Customization:** Face-to-face coaching allows for highly customized triggers, as coaches can listen, empathize, and tailor their message based on individual conversations, addressing specific social determinants of health. * **Hyper-Communication Strategy:** Serigraph's success involved utilizing a multitude of communication channels—in-person meetings, emails, flyers, HR staff, managers—to ensure messages reached employees and their families effectively. Key Concepts: * **BJ Fogg's Behavior Model (B=MAT):** A framework stating that behavior change occurs when motivation, ability, and a trigger converge simultaneously. * **Action Line:** A graphical representation within Fogg's model indicating the threshold of motivation and ability required for a trigger to be effective. * **Ethos, Pathos, Logos:** Ancient Greek principles of persuasion: Ethos (credibility), Pathos (empathy), Logos (logic). The video emphasizes the importance of establishing ethos and pathos before presenting logos in healthcare communication. Examples/Case Studies: * **Serigraph:** An automotive parts manufacturer in Wisconsin that kept its healthcare costs flat for almost 10 years. Their strategy included monetary and time-off incentives, an on-site primary care clinic, and extensive, personalized communication including mandated annual face-to-face coaching.
Benefits of a Two Layer Regulatory Intelligence Platform
IMTF - Excellence in RegTech Solutions
/@imtf-excellenceinregtech
Mar 11, 2022
The speaker, Gion-Andri Büsser of IMTF, discusses the critical need for modern technology in compliance, driven by exploding costs of compliance and even higher costs of non-compliance. He introduces a "two-layer regulatory intelligence platform" concept, emphasizing an orchestration layer that centralizes the treatment of compliance alerts, automates processes, fosters collaboration, and provides a holistic view of data. The video highlights how advanced technologies, including machine learning and data science, can be leveraged within this architecture to significantly reduce manual work, improve efficiency, and enhance risk management. Key Takeaways: * **Ecosystem Approach to Compliance Technology:** The video advocates for viewing compliance technology as an integrated ecosystem rather than disparate, siloed software packages. This platform approach is crucial for comprehensive data utilization and decision-making. * **The Power of the Orchestration Layer (Layer 2):** A dedicated orchestration layer is presented as essential for consolidating and processing all compliance alerts (e.g., AML, fraud, sanctions), enabling flexible process automation, fostering collaboration across teams, and maintaining accurate, regulator-ready audit trails. * **AI/ML for Enhanced Efficiency and Risk Reduction:** The "magic" of the orchestration layer lies in its ability to leverage AI and machine learning for advanced functions such as intelligent auto-closure of routine alerts, pre-processing to highlight historical patterns, and more granular, accurate risk rating based on comprehensive customer history. * **Strategic IT and Change Management Benefits:** Implementing an orchestration layer provides significant IT flexibility, allowing organizations to introduce modern tools and interfaces without immediately replacing existing, potentially valuable, legacy detection systems (Layer 1). This enables a phased modernization approach, reducing disruption and risk. * **Continuous Adaptation to Evolving Threats:** The speaker underscores that financial crime and compliance challenges are an "ever-ending battle," with criminal behaviors constantly evolving (e.g., due to pandemics, crypto). This necessitates adaptive, forward-looking technology to anticipate and combat new threats.g., GxP, 21 CFR Part 11, FDA/EMA regulations).
Veeva Systems (VEEV) Stock Analysis and Intrinsic Value | Buy Now or Wait?
Andrew Finance
/@andrewfinance5351
Mar 11, 2022
This video provides a detailed financial and technical analysis of Veeva Systems (VEEV) stock, assessing its intrinsic value using Discounted Cash Flow (DCF) and Earnings Per Share (EPS) models under various performance scenarios. It delves into Veeva's business strengths, risks, and future growth prospects, ultimately providing an investment recommendation. The analysis highlights Veeva's strong market position as a cloud-computing leader in the pharmaceutical and life sciences industries, its robust financial health, and its strategic expansion into other regulated sectors. Key Takeaways: * **Veeva's Dominance in Life Sciences:** Veeva Systems is firmly established as a leading cloud-computing provider for the pharmaceutical and life sciences industries, characterized by strong subscription revenue, high switching costs, and a strategic relationship with Salesforce, which limits competition in its core niche. * **Robust Financial Health and Growth Outlook:** The company demonstrates excellent profitability with a 23% profit margin, 11% return on assets, and 15% return on equity, coupled with a strong balance sheet. It is projected to achieve significant revenue growth (14% yearly) and EPS growth (10% yearly) over the next five years, indicating a healthy and expanding ecosystem for Veeva-centric solutions. * **Strategic Market Expansion:** Veeva has begun extending its content and data management solutions beyond life sciences into other regulated sectors such as consumer goods, chemicals, and cosmetics, signaling potential future growth avenues and broader applicability of its platform. * **Competitive Landscape and Operational Risks:** Despite its specialized market, Veeva faces competition from major enterprise software vendors like Oracle and Microsoft. Key risks include potential slowdowns in near-term growth due to labor pressures or challenges in closing large deals, customer churn, commercial execution issues, and litigation. * **Market Valuation Perspective:** The analysis concludes that Veeva stock is currently overvalued, recommending investors wait for signs of reversal or a price drop below $130 before considering an investment.
Case Study 2: Environment for Regulatory Submission
TransCelerate BioPharma
/@TransCelerateBioPharma
Mar 11, 2022
This video provides an in-depth exploration of how biopharmaceutical companies and Contract Research Organizations (CROs) can modernize their statistical computing environments, particularly for regulatory submissions. Presented by TransCelerate BioPharma, a non-profit organization focused on accelerating and simplifying R&D, the discussion highlights the urgent need for cutting-edge technologies like machine learning, artificial intelligence, and natural language processing in regulated R&D. The core challenge addressed is the current limitation imposed by traditional software and narrow regulatory guidance, which struggles to accommodate the emergence of electronic and digital data sources and the advanced analytical capabilities required to process them. The presentation introduces TransCelerate's "Framework for Modernization of Statistical Environment" (MSA environment). This framework outlines a set of principles designed to help organizations build and maintain a computing environment that health authorities will find reliable, ensuring that analytical outputs can be used with confidence to support regulatory filings. The foundational principles of this framework are Accuracy, Reproducibility, and Traceability (ART), which are emphasized as core tenets that must be cohesively integrated. The framework demonstrates that an MSA environment, whether utilizing traditional or non-traditional software, can produce accurate and reproducible results, supported by comprehensive documentation that traces the lineage of dependencies for each output. This end-to-end control, based on ART, is crucial for building health authority confidence in the efficacy and safety results of new drug candidates. The video details the practical implementation of the MSA framework, outlining phases such as pre-planning, design, implementation, and production. It identifies key stakeholders essential for success, including statisticians, programmers, clinical quality teams, IT professionals, and engineers. A critical success factor highlighted is the early engagement and cohesive collaboration among these multi-functional teams (clinical, pharma, and IT) to co-design a feasible and aligned plan. A specific case study is presented, currently in the production phase, where a multi-server computational environment was built. This environment features two types of open-source installations: one for exploratory and general work, and a "frozen" installation specifically for submission-related work, with all packages verified and tested against the MSA framework's guidance. The case study revealed significant benefits, such as demonstrating the validity of non-traditional tools through the framework's comprehensive guidance on testing and assessing accuracy, thereby mitigating risks related to trustworthiness. Challenges encountered included a lack of familiarity with the new environment among some stakeholders, necessitating clear communication between business and IT, and the substantial effort, time, and resources required for frequent updates before reaching equilibrium. To address these, dedicated data science teams were assigned, automated testing was maximized, and package validation was prioritized based on upcoming submission needs. The video concludes by emphasizing that the MSA framework is timely, enabling companies to proactively prepare for future health authority submissions and fostering a necessary cultural shift towards more malleable operations and modern computing solutions across the biopharmaceutical industry. This collective effort to build health authority confidence in advanced analytical software is seen as vital for accelerating drug development and bringing innovative therapies to market faster. Key Takeaways: * **Urgent Need for Modernization:** The biopharmaceutical industry faces an undeniable need for cutting-edge technologies to transform the analytical life cycle due to the rapid growth of electronic and digital data (e.g., wearables, EHR) and the limitations of traditional software. * **Regulatory Challenges with New Technologies:** Current regulatory guidance narrowly defines reliable software, pushing companies to use older technologies and creating challenges for adopting advanced tools like machine learning, AI, and natural language processing in regulated R&D environments. * **TransCelerate's MSA Framework:** The "Framework for Modernization of Statistical Environment" (MSA environment) provides a structured approach for building and maintaining a modern computing environment that health authorities will find reliable for regulatory filings. * **Core Principles: Accuracy, Reproducibility, Traceability (ART):** The MSA framework is founded on the principles of Accuracy, Reproducibility, and Traceability, which must be cohesively integrated to ensure confidence in the reliability of efficacy and safety results for new drug candidates. * **Applicability to All Software:** The MSA environment framework applies to both traditional and non-traditional software, demonstrating how to produce accurate and reproducible results with comprehensive documentation tracing the lineage of dependencies for each output. * **Phased Implementation Approach:** Implementing the MSA framework involves distinct phases: pre-planning, design, implementation, and production, each with specific considerations, stakeholders, and potential challenges. * **Critical Stakeholder Collaboration:** Effective collaboration among diverse roles—statisticians, programmers, clinical quality, IT, and engineering—is paramount for successfully advancing statistical computing environments and co-designing feasible plans. * **Case Study: Frozen Environments for Submission:** A practical case study involved building a multi-server computational environment with separate installations for exploratory work and "frozen" installations for submission-related work, with packages verified using the MSA framework. * **Benefits of the Framework:** The framework offers excellent guidance for testing and assessing accuracy, demonstrating the validity of non-traditional tools and mitigating potential risks around their trustworthiness for regulatory use. * **Communication is Key for Stakeholder Alignment:** A significant challenge is ensuring all stakeholders, particularly business and IT, are familiar with new environments and work closely together to bridge communication gaps. * **Resource Allocation for Updates:** Organizations must plan for substantial effort, time, and resources for frequent updates and adjustments to the environment to meet evolving demands and company focus. * **Strategies for Addressing Challenges:** Solutions include assigning dedicated data science teams, leveraging automated testing as much as possible, and prioritizing package validation based on upcoming submission requirements. * **Cultural Shift Towards Malleability:** A broader cultural shift is needed within organizations to adopt more malleable approaches to operations, embracing modern computing solutions and frameworks to accelerate industry transformation. * **Opportunity Cost of Delay:** Delaying the adoption of innovative software capabilities carries an opportunity cost, ultimately impacting the industry's ability to bring drugs to market faster. * **Building Health Authority Confidence:** The framework provides an industry-wide approach for demonstrating the reliability of analytical software, including emerging tools, thereby building health authority confidence and facilitating the modernization of statistical tools. Key Concepts: * **Modernized Statistical Analytical (MSA) Environment:** A computing environment designed and maintained according to specific principles (ART) to ensure its reliability and trustworthiness for supporting regulatory filings with health authorities. * **Accuracy, Reproducibility, Traceability (ART):** The three core tenets of the MSA framework. Accuracy refers to the correctness of results, Reproducibility ensures that the same results can be obtained under the same conditions, and Traceability means that results can be linked back to their original data, code, and processes. * **Non-traditional Analytical Tools:** Advanced computational methods and software beyond conventional statistical packages, including Machine Learning (ML), Artificial Intelligence (AI), and Natural Language Processing (NLP). * **Frozen Installations:** A specific, controlled version of a software environment (including libraries and dependencies) that is kept static and unchanged for submission-related work to guarantee consistency, reproducibility, and compliance. Examples/Case Studies: * **Case Study 2: Environment for Regulatory Submission:** This case study details the implementation of a multi-server computational environment. It features two distinct types of open-source installations: one for general exploratory work and another, "frozen" installation specifically designed for submission-related work, with its packages verified and tested according to the MSA framework's guidance.
All the Places You’ll Grow with this Revolutionary Software Company
WayUp
/@WayUp
Mar 7, 2022
This video provides an in-depth exploration of Veeva Systems, a cloud-based software company specializing in the life sciences industry, focusing specifically on its "Generation Veeva" new graduate development programs and the career progression opportunities they offer. The event, hosted by WayUp, features Sarah Young, who oversees Veeva's new grad programs, and a panel of three alumni from the Consultant Development Program (CDP): Kyle Stevenson (Director of Product Management), Mary Molnar (Account Executive), and Rebecca Wright (Practice Manager). The primary purpose is to inform prospective new graduates about Veeva's culture, values, business model, and the various entry points available for starting a career in a rapidly growing, impactful sector. The discussion begins with an overview of Veeva's core identity as a software company that builds innovative solutions for the life sciences industry, serving end-users in pharma, med device, and clinical trial organizations. Veeva's comprehensive offering extends beyond just software to include integrated data solutions for customer insights, an in-house services team for product implementation, and a business consulting organization focused on commercial strategy and operations. With over 1100 global customers, including top pharma companies, and a workforce of over 5000 employees aiming for 10,000 by 2025, Veeva positions itself as the "industry cloud for life sciences." The company's values—do the right thing, customer success, employee success, and speed—are highlighted as foundational to its decision-making, underscored by its recent conversion to a public benefit corporation with a legal obligation to balance shareholder interests with those of customers, employees, and communities. A significant portion of the video is dedicated to detailing Veeva's five "Generation Veeva" development programs in the US: the Engineering Development Program (EDP), Consultant Development Program (CDP), Business Consultant Development Program (BCDP), Analytics Development Program (ADP), and Sales Development Program (SDP). Each program is designed to recruit top university talent and develop their careers in a supportive environment, adhering to values of "learn by doing," "developing the person," and "having fun." The panelists, all CDP alumni, then share their personal journeys, illustrating how the foundational skills gained in the CDP—covering consulting basics, software implementation, project management, and industry knowledge—prepared them for diverse roles within Veeva, from product development and sales to people management within services. They emphasize the dynamic nature of careers at Veeva, driven by continuous growth and innovation, and offer advice to new graduates on navigating their early career choices. Key Takeaways: * **Veeva's Industry Focus and Growth:** Veeva is a leading cloud-based software company dedicated to the life sciences industry, including pharmaceutical, biotech, and medical device sectors. It boasts over 1100 global customers and is rapidly expanding, aiming to double its 5000+ employee base to 10,000 by 2025, indicating significant career opportunities. * **Comprehensive Service Offering:** Beyond software, Veeva provides integrated data solutions for customer insights, in-house services for product implementation, and business consulting for commercial strategy and operations, aiming to build the "industry cloud for life sciences." * **Values-Driven Culture:** Veeva operates with core values of "do the right thing," "customer success," "employee success," and "speed." Its conversion to a public benefit corporation legally formalizes its commitment to balancing shareholder interests with those of customers, employees, and communities. * **"Generation Veeva" Development Programs:** Veeva offers five distinct new grad programs: Engineering (EDP), Consultant (CDP), Business Consultant (BCDP), Analytics (ADP), and Sales (SDP). These programs are designed to provide a strong foundation and accelerate career growth within the company. * **Consultant Development Program (CDP) Versatility:** The CDP is highlighted as a foundational program open to all majors (not just STEM), not requiring coding. It teaches consulting 101, software implementation, project management, and industry knowledge, serving as a springboard for various career paths including consulting, sales, and product management. * **Diverse Career Progression Paths:** Panelists exemplify varied career trajectories from the CDP: Kyle moved into Product Management (Director of Product Management for ePRO), Mary transitioned to an Account Executive role, and Rebecca advanced to a Practice Manager position within technical consulting, demonstrating internal mobility and growth. * **Hands-on Learning and Professional Development:** Veeva emphasizes a "learn by doing" approach within its development programs. The company also supports professional development through funding for further education, as demonstrated by Mary pursuing a Master of IT Project Management. * **Impactful Work:** Employees at Veeva contribute to building solutions that help the life sciences industry develop and commercialize new medicines more efficiently, ultimately impacting clinical research sites, patients, and doctors. * **Embrace Open-Mindedness and Challenge:** New graduates are advised to be open-minded about career options, pursue roles that energize them, and be willing to step out of their comfort zones, as this often leads to significant personal and professional growth. * **Work Hard and Smart:** A key piece of advice is to strive to work hard and be productive, combining both "smart" and "hard" work to achieve significant career advancement. * **Become a "Guru":** Aspiring professionals should aim to become an expert or "guru" in a specific product, application, functionality, or topic. This makes them a go-to resource and helps them get noticed and engaged in their work. * **Trust the Process and Seek Guidance:** It's normal not to have a perfectly defined career path. Trusting that doing good work in an enjoyable, challenging environment will lead to new opportunities, coupled with seeking guidance from experienced colleagues, is a valuable approach. * **Value of Candid Feedback:** Veeva's culture promotes candid feedback, which helps employees understand their performance, identify areas for growth, and feel recognized for their achievements. Tools/Resources Mentioned: * **Veeva Vault eTMF:** An electronic trial master file application, mentioned by Kyle as his entry point to Veeva's products. * **Veeva ePRO (Electronic Patient Reported Outcomes):** A new application being built by Kyle's team to gather patient information in clinical trials. * **WayUp:** The job platform hosting the virtual event. * **LinkedIn:** Mentioned as a platform for professional networking and connecting with Veeva employees. Key Concepts: * **Industry Cloud for Life Sciences:** Veeva's vision to provide a comprehensive, integrated suite of software, data, and services tailored specifically for the pharmaceutical, biotech, and life sciences sectors. * **Public Benefit Corporation (PBC):** A legal designation adopted by Veeva, signifying a commitment to balance the interests of shareholders with those of customers, employees, and the communities it serves. * **Generation Veeva:** The collective name for Veeva's new graduate development programs, designed to recruit and develop university talent. * **Consultant Development Program (CDP):** A flagship new grad program at Veeva focused on training individuals in consulting, software implementation, project management, and industry knowledge for life sciences. Examples/Case Studies: * **Kyle Stevenson's Journey:** Started as a clinical study administrator, manually filing paper documents. He discovered Veeva Vault eTMF when his company implemented it, became an internal expert, and then joined Veeva's CDP. He progressed to Director of Product Management, leading the development of the new ePRO application, which spans clinical operations, site engagement, and patient-facing web/mobile applications. * **Rebecca Wright's Progression:** Joined Veeva's CDP after realizing a lab career wasn't for her. She became an expert in implementing clinical applications for smaller customers. Her passion and performance led to her being selected to lead a team, eventually becoming a Practice Manager overseeing a team of consultants and designing product implementation strategies. * **Mary Molnar's Path:** With a background in psychology and clinical research, Mary joined the CDP, gaining hands-on experience in configuring systems, solution design, and project management for clinical applications. Leveraging professional development funding for a Master of IT Project Management, she transitioned through the Sales Development Program to become an Account Executive, acting as a strategic advisor to pharmaceutical and biotech customers.
Almost HALF of Cardiovascular Disease in Diabetes NOT TREATED!!
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Mar 5, 2022
This video provides an in-depth exploration of the alarming under-treatment of cardiovascular disease (CVD) in patients with diabetes, despite the availability of highly effective and affordable medications. Dr. Eric Bricker begins by outlining the pathophysiology of atherosclerosis, explaining how diabetes exacerbates the hardening and narrowing of arteries, leading to critical conditions such as heart attacks, strokes, and peripheral vascular disease (PVD). He emphasizes that PVD, often affecting the feet, can result in non-healing ulcers, gangrene, and amputations, while strokes are essentially "heart attacks of the brain" caused by similar atherosclerotic processes. The speaker highlights that this disease is "silent," meaning patients often feel fine until a catastrophic event occurs, making proactive treatment crucial. The presentation then details three categories of evidence-based treatments for diabetic patients with atherosclerosis: statin medications (e.g., Lipitor, Crestor) for cholesterol lowering, ACE inhibitors or Angiotensin Receptor Blockers (ARBs) for blood pressure control and organ protection (heart, blood vessels, kidneys), and newer medications like SGLT2 inhibitors and GLP-1 receptor antagonists that improve outcomes. The core issue is revealed through a study published in the Journal of the American Medical Association (JAMA) in February 2022. This study, encompassing hundreds of thousands of patients across 12 hospital systems, found that a staggering 43% of individuals with diabetes and cardiovascular disease received *zero* evidence-based treatments. Furthermore, only 20% received both statins and ACE inhibitors/ARBs, despite these being generic, "dirt cheap," and available for decades. Dr. Bricker critically examines the reasons behind this significant "gap in evidence-based care." He argues that the problem is not a lack of medical discovery but a profound failure in implementation within the American healthcare system. He points out that the fee-for-service payment model offers no accountability for doctors to follow evidence-based guidelines. Even existing value-based payment programs, including commercial and Medicare initiatives, are failing to move the needle on these statistics. Given that diabetes prevalence is growing (from 8% to 13% of adults in America over 20 years), this under-treatment represents a massive and escalating problem. The speaker concludes by asserting that employers, who bear the financial risk for their employees' health plans, must "own this problem" of implementation, as it is solvable and directly impacts their financial burden and employee well-being. Key Takeaways: * **Widespread Under-treatment:** A JAMA study revealed that 43% of patients with diabetes and cardiovascular disease receive no evidence-based treatments, and only 20% receive the two well-established, affordable treatments (statins and ACE inhibitors/ARBs). * **Pathophysiology of Atherosclerosis:** Diabetes significantly worsens atherosclerosis (hardening and narrowing of arteries) by making cholesterol plaques "extra sticky," while hypertension increases the likelihood of these plaques rupturing, leading to severe blockages. * **Consequences of Untreated Atherosclerosis:** This silent disease can lead to heart attacks, strokes, peripheral vascular disease (causing non-healing foot wounds, gangrene, and amputations), and kidney failure requiring dialysis. * **Effective and Affordable Treatments Exist:** Established treatments like statins (cholesterol-lowering) and ACE inhibitors/ARBs (blood pressure and organ protection) have been available for over two decades, are generic, and are "dirt cheap," often costing just a few dollars a month. Newer medications like SGLT2 inhibitors and GLP-1 receptor antagonists also improve outcomes. * **"Gaps in Evidence-Based Care":** This medical jargon refers to the failure to implement known, effective treatments that prevent severe cardiovascular events and complications in diabetic patients. * **Implementation Problem, Not Discovery Problem:** The core issue is not a lack of scientific discovery or effective medications, but rather a systemic failure in the healthcare infrastructure to ensure these proven treatments are consistently applied to patients who need them. * **Failure of Current Payment Systems:** The fee-for-service model provides no accountability for physicians to adhere to evidence-based guidelines. Critically, even existing value-based payment programs in commercial insurance and Medicare are not effectively addressing these treatment gaps. * **Growing Public Health Crisis:** The prevalence of diabetes in American adults has increased significantly (from 8% to 13% in 20 years), exacerbating the impact of this under-treatment problem on individuals and the healthcare system. * **Employers Bear Financial Risk:** Employers sponsoring health plans are ultimately responsible for the financial burden of poor patient care and preventable complications arising from untreated cardiovascular disease in their diabetic employees. * **Call to Action for Employers:** Employers are urged to "own this problem" of implementation, as it is solvable and crucial for reducing their financial risk and improving the health of their plan members. * **Physician Engagement is Key:** The study found that 75% of these under-treated patients had been seen by a primary care physician or cardiologist, indicating that the issue often lies with physician adherence to guidelines or patient engagement strategies. Tools/Resources Mentioned: * Journal of the American Medical Association (JAMA) - cited study from February 17, 2022. * CDC National Diabetes Statistics Report - referenced for diabetes prevalence data. Key Concepts: * **Atherosclerosis:** A disease in which plaque builds up inside your arteries, causing them to harden and narrow, restricting blood flow. * **Peripheral Vascular Disease (PVD):** A circulatory condition in which narrowed blood vessels reduce blood flow to the limbs, often leading to non-healing wounds, ulcers, and potential amputation. * **Statins:** A class of drugs used to lower cholesterol levels in the blood. * **ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors) / ARBs (Angiotensin Receptor Blockers):** Medications primarily used to treat high blood pressure and heart failure, also protective for the heart, blood vessels, and kidneys. * **SGLT2 Inhibitors / GLP-1 Receptor Antagonists:** Newer classes of medications for diabetes that have also shown significant cardiovascular and renal benefits. * **Evidence-Based Care:** Medical care that is supported by clinical research and scientific evidence. * **Fee-for-Service:** A payment model where healthcare providers are paid for each service they provide. * **Value-Based Payment:** A payment model that rewards healthcare providers for quality of care and patient outcomes, rather than quantity of services.
TMF & Quality Control
Power of Work
/@powerofwork6914
Mar 4, 2022
This video provides a comprehensive overview of Trial Master File (TMF) quality control (QC) within clinical trials, emphasizing its critical role in regulatory compliance and drug approval. The speaker details how TMF documentation serves as proof of a drug's safety and efficacy, ensuring adherence to Good Clinical Practices (GCP) and ICH guidelines. The discussion covers the practical aspects of TMF management, including the use of electronic TMF (eTMF) systems like Veeva, the importance of TMF maps and plans for document organization, and the meticulous process of performing QC checks. These checks involve verifying document completeness, correct filing, metadata accuracy, and the presence of required signatures, all while safeguarding patient privacy. The video highlights the challenges of managing vast amounts of documentation and the necessity for rapid document retrieval during audits and inspections. Key Takeaways: * **TMF as a Regulatory Cornerstone:** The TMF is indispensable for demonstrating regulatory compliance (FDA, ICH, GCP) in clinical trials, serving as the primary evidence for drug safety, efficacy, and patient protection. * **Operational Efficiency through Organization:** Effective TMF management, utilizing tools like the TMF Reference Model and company-specific TMF plans, is crucial for maintaining organized documentation and enabling rapid retrieval, which is vital during audits and inspections. * **Meticulous Quality Control is Paramount:** A rigorous QC process for TMF documents is essential, focusing on completeness, accurate metadata, correct filing, signature verification, and the absence of Protected Health Information (PHI) to ensure audit-readiness. * **Veeva's Role in eTMF Management:** The video explicitly mentions Veeva as a common system for managing eTMFs, underscoring the prevalence of specialized software in handling the complexities of clinical trial documentation. * **Challenges and Opportunities for Automation:** The manual and time-intensive nature of TMF QC, coupled with the high volume and complexity of documents, presents significant challenges that could be addressed through advanced automation and AI solutions for classification, metadata extraction, and compliance checks. * **The "Gatekeeper" Role of TMF Processors:** Document specialists act as critical "gatekeepers," ensuring the integrity and accuracy of the TMF, identifying discrepancies, and clearly documenting findings for resolution by document owners, thereby upholding the overall quality of clinical trial records.
Investing in Companies that Earn Profits #veeva #iqvia #nvidia #thermofisher #adobe
Animal Donut
/@animaldonut
Feb 24, 2022
This video provides an in-depth exploration of how to identify profitable companies for long-term investment, moving beyond mere stock price fluctuations to focus on underlying business fundamentals. The speaker, Jeff Luke, a professional photographer and author of "Stock Market Intelligence," aims to equip investors with tools to analyze a company's financial health. He emphasizes the importance of understanding revenues, operating expenses, and net income to determine true profitability, contrasting this approach with speculative investing in companies that may not yet be generating profits. The core message is that long-term investment success is rooted in becoming a part-owner of a fundamentally sound, profitable business. The presentation progresses by first setting the stage for a more informed investment strategy, highlighting the distinction between short-term market "voting" (price movements) and long-term "weighing" (business fundamentals). Luke then illustrates his methodology by examining five specific companies, all of which he personally holds stock in, providing their trailing 12-month (TTM) revenues, operating income, and net income. He explicitly mentions his preference for investing in industries he understands well, particularly the life sciences, which informs his selection of companies like Veeva Systems, Iqvia, and Thermo Fisher Scientific. This approach underscores the value of industry knowledge in making confident, long-term investment decisions. The video details the financial performance and market positioning of each selected company. Veeva Systems is highlighted as a leading provider of cloud-based software for the life sciences industry, known for its profitability. Iqvia is presented as a dominant contract research organization (CRO) and a key player in life sciences data and analytics. Nvidia's role as a top designer of GPUs, crucial for enhancing visual computing and powering technologies like autonomous vehicles, is discussed. Thermo Fisher Scientific is identified as the premier life sciences supplier, offering a vast portfolio of devices and machinery for scientific analysis. Finally, Adobe Systems is recognized for its dominance in content creation software through its Creative Cloud subscription model. For each, specific financial figures are provided, reinforcing the video's focus on tangible profitability metrics. Ultimately, the video advocates for a disciplined, fundamental-driven investment strategy. Luke encourages viewers to always ascertain a company's profitability before investing, fostering a category of investor who makes decisions based on clear financial understanding rather than chasing "hot stocks." He stresses that investing in well-run, profitable businesses provides confidence, reduces the need for constant market monitoring, and aligns with a long-term holding strategy, allowing investors to "buy it and then just put it away." Key Takeaways: * **Prioritize Profitability in Investing:** Investors should always determine if a company is earning profits or suffering losses before making an investment, moving beyond mere stock price movements to understand the underlying business health. * **Understand Core Financial Metrics:** Key indicators of a company's financial health include revenues (money taken in), operating income (money left after operating expenses), and net income (final profit after all costs). These are crucial for assessing true profitability. * **Access Financial Data:** Basic financial statement information, including income statements, can be found on a company's website (annual/quarterly reports) or through financial services like Value Line and Morningstar. * **Veeva Systems' Market Position:** Veeva is a profitable, leading provider of cloud-based software solutions specifically for the life sciences industry, making it a significant player in a specialized and regulated sector. * **Iqvia's Dominance in Life Sciences:** Iqvia is a profitable and dominant contract research organization (CRO) and a key player in life sciences data and analytics, serving a critical role in drug development and healthcare insights. * **Nvidia's GPU Leadership:** Nvidia is the top designer of Graphics Processing Units (GPUs), which are essential for enhancing visual computing platforms and are increasingly vital for AI applications, including autonomous vehicles. * **Thermo Fisher Scientific as a Life Sciences Giant:** Thermo Fisher Scientific is described as the premier life sciences supplier, providing a wide array of devices, machinery, and services used for analysis and research within the life sciences industry. * **Adobe's Content Creation Monopoly:** Adobe Systems dominates the content creation software market with iconic products like Photoshop and Illustrator, operating on a successful subscription model (Creative Cloud). * **Speaker's Investment Philosophy:** The speaker, Jeff Luke, emphasizes investing in industries one understands well (e.g., life sciences) to better grasp a company's relative strength and dominance, leading to more confident, long-term investment decisions. * **Long-Term vs. Short-Term Investing:** The video distinguishes between short-term market "voting" (speculation based on price) and long-term "weighing" (investment based on business fundamentals and profitability), advocating for the latter. * **Confidence in Well-Run Companies:** Investing in consistently profitable and well-run companies provides confidence, reducing the need for frequent trading decisions and allowing for a "buy it and put it away" long-term strategy. * **Avoid Speculation Without Awareness:** While speculating on unprofitable companies is an option, investors should be fully aware of the inherent risks and understand that such ventures are not based on current profitability. Tools/Resources Mentioned: * Company annual reports * Company quarterly reports * Value Line (financial research service) * Morningstar (financial research service) * "Stock Market Intelligence" (book by Jeff Luke) * "Crush It With ETFs" (book by Jeff Luke) * "The ETF Investor" (book by Jeff Luke) * Sony ZV-1 (camera used for filming) * Joby TelePod Mobile Tripod (tripod used for filming) Key Concepts: * **Revenues:** The total amount of money a company generates from its sales of goods or services before any expenses are deducted. * **Operating Income:** A company's profit after subtracting operating expenses (such as wages, depreciation, and cost of goods sold) from revenues, but before deducting interest and taxes. * **Net Income:** The total profit of a company after all expenses, including operating costs, interest, and taxes, have been deducted from revenues. Often referred to as "the bottom line." * **Trailing 12 Months (TTM):** A financial metric that represents the sum of a company's financial performance over the past 12 consecutive months, providing a more current view than annual reports. * **Contract Research Organization (CRO):** An organization that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. * **Graphics Processing Unit (GPU):** A specialized electronic circuit designed to rapidly manipulate and alter memory to accelerate the creation of images in a frame buffer intended for output to a display device. GPUs are crucial for AI and machine learning. * **Creative Cloud:** Adobe's subscription service that provides users with access to a collection of software developed by Adobe for graphic design, video editing, web development, photography, and more. * **"Voting" vs. "Weighing":** An investment analogy where "voting" refers to the short-term market sentiment and price fluctuations (how the market "votes" on a stock), while "weighing" refers to the long-term assessment of a company's intrinsic value based on its fundamentals (how the market "weighs" the business over time).
Best practices for creating and maintaining a library of data collection standards
SCDM - Society for Clinical Data Management
/@SCDMchannel
Feb 24, 2022
This video provides an in-depth exploration of best practices for creating, implementing, and maintaining a library of data collection standards within clinical research, with a particular focus on leveraging Veeva Vault CDMS/EDC. Richard Young, VP Strategy at Veeva, sets the stage by outlining the critical benefits of data standards, such as reducing cycle times, improving data quality, enhancing compliance, and ensuring consistency across studies. He highlights common challenges in standardization, including difficulty getting started, lack of ownership, proliferation of standards, overstuffed standards, and outdated practices. The presentation emphasizes aligning with industry standards like CDISC (C-Dash) and SDTM, keeping the end in mind for downstream processes, and adopting a site and patient-centric approach. Jen Showalter, an industry expert in data standards, then presents a case study from Eli Lilly, detailing their journey in building and maintaining a library-driven approach for Veeva Vault CDMS. She describes Lilly's phased approach, starting with identifying frequently used forms, collaborating with end-to-end stakeholders (from sites to statisticians and medical teams), and establishing robust governance. A key recommendation is to build new forms from scratch within the library rather than copying old practices, leveraging new tool capabilities like progressive displays and form linking, and ensuring a unique "library key" is assigned to each object for effective tracking. The discussion delves into the specific components managed within their Veeva Vault CDMS library, including events, forms, item groups, items, code lists, and various user-defined rules (dynamic, data verification, set value, subject status, and email rules). Beyond the system, Lilly also manages external documentation like allowable changes, data check specifications, and completion guidelines, stressing the importance of aligning these with the library's version. The presentation further elaborates on the maintenance and governance of the library. Lilly employs a master-level management approach to minimize variations, using guidance to inform study designers on allowable changes. They set clear expectations for library usage, aiming for high adherence (e.g., 80% usage) while having a tiered governance process to review and approve necessary deviations quickly. A crucial tool for monitoring compliance and informing maintenance is the system-generated difference report from Veeva EDC, which tracks divergences between study objects and library objects. This report also enables a risk-based approach to testing, reducing rework. Changes to the library can originate from external sources (regulatory, industry standards like CDISC/SDTM, system enhancements from Veeva releases) or internal feedback from studies. All change requests are tracked in a centralized system, informing quarterly maintenance cycles and allowing for impact assessments. The presentation concludes by highlighting the realized benefits, including allowing study teams to focus on unique scientific aspects, improved site experience, downstream efficiencies for data management, medical review, and biostatistics, enhanced automation, reduced study build cycle times, minimized rework, and improved data quality. Key Takeaways: * **Strategic Importance of Data Standards:** Data collection standards are crucial for reducing clinical trial cycle times, improving data quality and consistency, enhancing regulatory compliance, and driving efficiencies across the entire data lifecycle, from design to reporting. * **End-to-End Stakeholder Collaboration:** Successful library implementation requires collaboration with all stakeholders, including sites (for user experience), medical affairs, statisticians, and data management, to ensure content meets diverse needs and facilitates adoption. * **Veeva Vault CDMS/EDC as a Foundation:** The Veeva Vault CDMS/EDC platform provides robust capabilities for building and managing a data standards library, including features for forms, items, code lists, user-defined rules, and form linking. * **Library-Driven Approach for Efficiency:** Starting with a well-defined library of standard templates (forms, events, rules) significantly reduces study build times and rework, allowing teams to focus on scientifically unique aspects of a study. * **"Library Key" for Tracking and Maintenance:** Each object in the library should have a unique identifier (library key) to track its lineage and usage across studies, enabling effective monitoring of adherence and informing future maintenance decisions. * **Build New, Don't Copy Old:** When establishing a library, it's more beneficial to build new forms and objects from scratch, leveraging modern tool capabilities, rather than replicating potentially inefficient legacy practices from existing studies. * **Comprehensive Governance Model:** A robust, tiered governance process is essential to manage change requests, ensure adherence to standards, and facilitate timely review of necessary deviations without slowing down study development. * **Minimize Variation, Maximize Guidance:** Instead of creating numerous variations of a standard within the library, manage core "master" standards and provide clear guidance (e.g., "allowable changes") to study designers on how to adapt them for specific study needs. * **Leverage System-Generated Reports:** Tools like Veeva's "difference report" and "library report" are invaluable for monitoring library usage, identifying divergences from standards, and informing a risk-based approach to testing, thereby reducing redundant testing efforts. * **Regular Maintenance Cycles:** Libraries are living entities and require regular maintenance cycles (e.g., quarterly) to incorporate new regulatory requirements, industry standards (CDISC, SDTM), system enhancements, and feedback from real-world study usage. * **Centralized Change Request System:** Implement a system to track all change requests, whether from internal feedback or external sources, to prioritize updates, document decisions (including reasons for not implementing a change), and inform maintenance cycles. * **Documentation Alignment and Accessibility:** All supporting documentation (completion guidelines, data check specifications, allowable changes) must be version-aligned with the library and easily accessible to all stakeholders to ensure consistent understanding and usage. * **Training and Communication are Key:** Continuous training and communication are vital to ensure all stakeholders, from new hires to experienced teams, understand the standards, their importance, and how to effectively use the library. * **Downstream Benefits Beyond Data Collection:** Standardization extends benefits to downstream processes, including improved data extraction for SDTM, streamlined statistical programming, enhanced medical review, and better integration with other clinical systems (e.g., CTMS). * **Resource Allocation for Library Support:** Dedicate a subset of study designers, including a "lead librarian," to support library maintenance, stakeholder discussions, change request management, and training, even if not fully dedicated to the library. Tools/Resources Mentioned: * Veeva Vault CDMS (Clinical Data Management Suite) * Veeva Vault EDC (Electronic Data Capture) * CDISC (Clinical Data Interchange Standards Consortium) / C-Dash (CDISC standards) * SDTM (Study Data Tabulation Model) * Veeva Studio (platform for library report) * System-generated difference report (from Vault EDC) * Library report (from Vault EDC Studio) * Lilly's internal request system/change log Examples/Case Studies: * **Eli Lilly's Implementation:** The entire presentation serves as a case study from Eli Lilly, detailing their multi-year effort to establish and mature their data collection standards library within Veeva Vault CDMS. * **Common Standard Forms:** Examples of forms prioritized for standardization include Demography, Inclusion/Exclusion, Informed Consent, Adverse Events, Medical History, Prior Therapies, and Exposure. * **Code List Variations:** Using distinct code lists for different therapeutic areas (TA1 vs. TA2) for a single disposition form allows for flexibility without creating multiple form variations in the library. * **Metadata for Downstream Transformations:** Using metadata like form name, release date, and version within the standard helps drive downstream transformations and identify differences across studies. * **FAQ Guidelines:** An example of an FAQ for units of measurement demonstrates how to provide instructions for geographically varied standards (e.g., US vs. global sites using Celsius vs. alternative units).
Managing Quality by Automating Corrective and Preventive Actions (CAPA)
ComplianceQuest
/@ComplianceQuest
Feb 22, 2022
This video provides an in-depth exploration of managing quality by automating Corrective and Preventive Actions (CAPA) using the ComplianceQuest CAPA Management solution. The presentation focuses on how this enterprise-grade system enables organizations, particularly within regulated industries, to detect and systematically address issues, mitigate risks, and drive continuous improvement. It outlines a comprehensive CAPA process from initial issue identification and risk assessment through investigation, containment, action planning, and effectiveness verification, emphasizing ease of use and robust functionality. The core of the solution lies in its structured approach to CAPA, beginning with detailed issue entry and priority identification, allowing for the connection of associated events across multiple sites or from the supply chain. A critical aspect highlighted is the integrated risk assessment capability, which helps organizations establish risk scores and prioritize CAPAs, ensuring that critical issues receive immediate attention. The system supports immediate containment actions, offering flexibility for multiple containment strategies, and facilitates thorough investigations using methodologies like the 5W2H problem-solving process and the graphical 5-Why root cause analysis tool. The video further elaborates on the distinction and application of corrective actions (to prevent recurrence) and preventive actions (to prevent occurrence), stressing the flexibility to implement either or both as appropriate for a given issue. A key feature is the automated effectiveness check, which schedules future reviews to confirm if implemented actions have resolved the issue and prevented recurrence. For complex scenarios, the system supports escalating CAPAs, relating them to original issues, and managing global CAPAs that trigger site-specific actions. It also integrates approval workflows at various stages to ensure consensus and compliance. Significantly, the solution leverages artificial intelligence to guide users through the CAPA lifecycle by suggesting next best steps, enhancing efficiency and user adoption. Beyond the core CAPA workflow, the ComplianceQuest solution demonstrates its interconnectedness with other quality management processes. It allows CAPAs to be initiated directly from audit findings, complaints, or non-conformances, and can drive changes throughout the organization via its change control solution. This includes updating documents, modifying processes, or implementing structural changes. The system also provides intuitive navigation, dashboards with key metrics and KPIs, and ad hoc reporting capabilities, empowering management teams with actionable insights and detailed analysis without the burden of data retrieval. Key Takeaways: * **Systemic Issue Detection and Risk Mitigation:** The ComplianceQuest CAPA solution empowers organizations to proactively identify and address systemic issues, thereby effectively mitigating risks across operations. This is crucial for maintaining quality and compliance in regulated environments. * **Comprehensive CAPA Lifecycle Management:** The solution covers the entire CAPA process, from initial issue identification and detailed entry, through investigation and root cause analysis, to the implementation of corrective/preventive actions and subsequent effectiveness checks. * **Integrated Risk Assessment and Prioritization:** Users can perform risk assessments to determine the impact and priority of each CAPA, enabling focused allocation of resources and efforts on the most critical issues first. This ensures efficient management of quality concerns. * **Advanced Investigation Tools:** The system incorporates industry-standard investigation methodologies such as the 5W2H problem-solving process and a built-in graphical 5-Why root cause analysis tool, facilitating thorough and structured investigations to uncover underlying causes. * **Flexible Corrective and Preventive Actions:** The solution differentiates between corrective actions (preventing recurrence) and preventive actions (preventing occurrence), offering the flexibility to implement either or both based on the specific nature of the issue. * **Automated Effectiveness Checks:** An automated effectiveness check feature schedules future reviews to verify if the implemented CAPA actions have successfully resolved the issue and prevented further events, driving continuous improvement. * **Scalable CAPA Management:** The system supports complex scenarios, including the escalation of CAPAs, linking them to original issues for historical context, and managing global CAPAs that can trigger and connect to site-specific CAPAs. * **Workflow-Driven Approvals:** Built-in approval workflows ensure that all activities throughout the CAPA lifecycle are reviewed and agreed upon by relevant stakeholders, enhancing accountability and compliance. * **Interconnected Quality Management:** The CAPA solution is seamlessly integrated with other quality management processes, allowing CAPAs to be generated from audit findings, complaints, or non-conformances, and driving changes through a dedicated change control solution. * **AI-Powered Guidance:** Artificial intelligence is leveraged to provide users with "next best steps" suggestions throughout the CAPA lifecycle, streamlining workflows, improving efficiency, and aiding user adoption. * **Actionable Business Intelligence:** Dashboards provide critical metrics and KPIs, while ad hoc reporting capabilities offer easy access to underlying data for detailed analysis, empowering management to make informed decisions and focus on continuous improvement. * **Focus on Continuous Improvement:** By systematically addressing issues, verifying effectiveness, and integrating with change control, the solution fosters a culture of continuous improvement in quality and operational excellence. Tools/Resources Mentioned: * ComplianceQuest CAPA Management solution * Salesforce (platform on which ComplianceQuest is built) * 5W2H problem-solving process * 5-Why root cause analysis tool (graphical) * ComplianceQuest Change Control solution Key Concepts: * **CAPA (Corrective and Preventive Actions):** A systematic process for identifying, documenting, investigating, and eliminating causes of nonconformities or other undesirable situations. Corrective actions address existing problems, while preventive actions prevent potential problems. * **Root Cause Analysis:** A method used to identify the underlying causes of a problem or event, rather than just addressing the symptoms. Tools like 5-Why and 5W2H are used for this. * **Effectiveness Check:** A follow-up verification process to ensure that the implemented corrective and preventive actions have successfully resolved the issue and prevented its recurrence. * **Containment Actions:** Immediate actions taken to prevent further damage or spread of an issue while a full investigation and CAPA process is underway. * **Risk Assessment:** The process of identifying potential risks, analyzing their likelihood and impact, and prioritizing them to determine which issues require immediate attention. * **Change Control:** A formal process used to ensure that changes to products, processes, or systems are introduced in a controlled and coordinated manner, often triggered by CAPAs. * **QMS (Quality Management System):** A formalized system that documents processes, procedures, and responsibilities for achieving quality policies and objectives. CAPA is a critical component of a QMS.
RIM 101 Part 1 - What is a RIM system?
Rimsys Inc.
/@rimsysinc.4269
Feb 21, 2022
This video provides an in-depth exploration of Regulatory Information Management (RIM) systems, specifically within the context of the medical technology (MedTech) industry. The presenter begins by establishing the critical role of regulatory affairs in ensuring that medical devices, in vitro diagnostics, and medical software can be legally marketed and maintained throughout their entire lifecycle. The core problem highlighted is the widespread scattering of essential regulatory information across various documents, software systems, and even individual employees' knowledge, leading to significant inefficiencies where regulatory professionals spend a substantial portion of their time simply searching for data. The presentation details the extensive responsibilities of regulatory affairs teams, which span from pre-market activities like assembling submissions for market clearance to on-market tasks such as tracking registration expirations, government regulations, and international standards. Furthermore, regulatory affairs takes the lead on post-market surveillance, including tracking adverse events and complaints, and ensuring appropriate reporting to health authorities. These activities are multiplied for every product sold in every regulated country or region, all heavily dependent on precise information like global regulations, product specifications, testing data, and a complete record of registrations and processes. RIM systems are introduced as the solution to these challenges, serving as a "single source of truth" for regulatory affairs teams. They centralize and manage all pertinent information by storing documents, integrating data from other software systems, and creating a traceable record of regulatory activities. This collected information is intuitively linked to individual products and market regions, significantly improving searchability and accessibility. The systems are designed to automate and streamline regulatory activities across the product lifecycle, acting as a collaborative digital hub for researching, authoring, and assembling documentation for new submissions, tracking changes in relevant standards and regulations, and facilitating the collection and analysis of post-market data for internal and health authority reporting. Underpinning these capabilities, RIM systems incorporate a full suite of compliant project planning, workflow management, approval, and reporting features. By implementing such systems, MedTech companies can drastically improve the efficiency and accuracy of their regulatory affairs operations. This, in turn, translates into tangible business benefits, including reduced revenue risk, strengthened global compliance, and a faster time to market for their products, ultimately enhancing their competitive position and operational integrity. Key Takeaways: * **Critical Role of Regulatory Affairs:** Regulatory affairs is indispensable throughout the entire product lifecycle in the MedTech industry, encompassing medical devices, in vitro diagnostics, and medical software, ensuring legal marketability and ongoing compliance. * **Comprehensive Regulatory Responsibilities:** Regulatory teams are responsible for pre-market activities (market clearance, submissions), on-market maintenance (tracking registrations, regulations, standards), and post-market surveillance (adverse events, complaints, health authority reporting). * **Information Management Challenge:** A significant hurdle for regulatory professionals is the fragmented nature of critical information, which is often scattered across various systems and documents, leading to up to half their time being spent on information retrieval. * **RIM Systems as a Single Source of Truth:** Regulatory Information Management (RIM) systems address this by providing a centralized, digitized repository that acts as a single source of truth for all regulatory information and content. * **Core RIM System Functionalities:** RIM systems store documents, integrate information from other software systems, create traceable records of regulatory activities, and intuitively link data to specific products and market regions for easy access. * **Automation and Streamlining of Activities:** These systems automate and streamline diverse regulatory activities across the product lifecycle, from initial submissions to ongoing compliance and post-market reporting. * **Collaborative Digital Hub:** RIM systems serve as a collaborative digital hub where teams can efficiently research, author, and assemble supporting documentation required for new regulatory submissions. * **Proactive Compliance Monitoring:** They track changes in relevant standards and regulations, helping companies identify potential impacts on their products and maintain proactive compliance. * **Enhanced Post-Market Surveillance:** RIM systems aid in collecting and analyzing post-market data, which is crucial for internal reporting and submissions to health authorities. * **Integrated Compliance Features:** Underlying the core capabilities are robust features for compliant project planning, workflow management, approval processes, and comprehensive reporting, ensuring adherence to regulatory requirements. * **Significant Business Benefits:** Implementing RIM systems leads to improved efficiency and accuracy in regulatory affairs, resulting in reduced revenue risk, strengthened global compliance, and a faster time to market for MedTech products. * **Target Industry Focus:** The discussion specifically targets the MedTech sector, highlighting the unique regulatory complexities faced by companies dealing with medical devices, IVDs, and medical software. Key Concepts: * **Regulatory Information Management (RIM) System:** A software solution designed to centralize, manage, and streamline all regulatory documentation, submissions, and maintenance processes for products in regulated industries. * **Regulatory Affairs:** The department or function within a company responsible for ensuring that products comply with relevant regulations and laws in the regions where they are marketed. * **MedTech (Medical Technology):** An industry sector encompassing medical devices, in vitro diagnostics (IVD), and medical software, all of which are subject to stringent regulatory oversight. * **Post-Market Surveillance:** The practice of monitoring the safety and performance of a medical product after it has been released for sale, including tracking adverse events, complaints, and reporting to health authorities. Tools/Resources Mentioned: * **Rimsys.io:** The website mentioned at the end of the transcript (www.rimsys.io/rim101) as a resource for learning more about RIM systems for MedTech regulatory affairs.
How CROs and Sponsors Improve TMF Management with a Shared eTMF - Agatha eTMF software
Agathalife EN
/@Agathalife_EN
Feb 18, 2022
This video provides an in-depth exploration of how Contract Research Organizations (CROs) and Sponsors can significantly improve Trial Master File (TMF) management through the adoption and collaborative use of a shared Electronic Trial Master File (eTMF) system. Presented by Ken Lownie, Head of North American Operations at Agatha, and Kari Brown, Director of Clinical Operations at DZS Clinical Services (a mid-sized CRO), the discussion moves beyond viewing the TMF as a mere document repository. It emphasizes its evolving role as a central engine for collaboration, process management, and ensuring regulatory compliance throughout the clinical trial lifecycle. The speakers highlight the critical relationships between stakeholders—Sponsors, CROs, Sites, and even Regulators—and how technology can foster trust, streamline operations, and enhance overall trial quality. The discussion begins by setting the stage on the importance of strong CRO-Sponsor relationships, contrasting "love fest" projects built on mutual trust and respect with "horror show" scenarios characterized by adversarial dynamics and excessive scrutiny. This foundation underscores the need for clear expectations, open communication, and a shared purpose. The conversation then transitions into the practicalities and challenges of TMF ownership and management, acknowledging the sponsor's ultimate legal responsibility while recognizing the common delegation of TMF duties to CROs. This leads to the core argument for a collaborative eTMF system that supports not just document storage but also active processes like remote monitoring, collaborative authoring, and robust workflow management. A significant portion of the webinar is dedicated to defining the characteristics of a "fourth-generation eTMF" and its role in advancing clinical operations along a "clinops technology adoption curve." This framework illustrates a progression from basic tools (spreadsheets, shared folders) to core systems (eTMF, CTMS, EDC), and ultimately to fully digitized, connected, and automated processes. The speakers detail how a modern eTMF facilitates seamless interaction between sites (via electronic Investigator Site Files or eISF), CROs, and sponsors, ensuring that all essential documents collectively "tell the story" of the clinical trial in a compliant and auditable manner. Kari Brown shares a compelling example of a fully virtual trial managed by DZS, demonstrating how advanced eTMF and eISF integration enables remote e-consenting, virtual visits, automated data capture, and comprehensive oversight, pushing towards a "nirvana stage" of digital clinical trials. Key Takeaways: * **Evolving Role of the TMF:** The Trial Master File is no longer just a static repository for documents but has evolved into a dynamic engine for collaboration, process management, and communication across all clinical trial stakeholders. Regulators, like the FDA, increasingly expect the TMF to comprehensively "tell the story" of the clinical trial. * **Shared Responsibility and Collaboration:** While the sponsor holds ultimate legal and regulatory responsibility for the TMF, its effective management often requires delegation to CROs. A shared eTMF system is crucial for fostering collaboration, ensuring transparency, and maintaining a unified, compliant record. * **Foundations of Strong Relationships:** Successful CRO-Sponsor partnerships are built on five key pillars: clear expectations (defined early through roles, responsibilities, and study plans), mutual respect for expertise, honest and open communication (especially regarding challenges and solutions), active collaboration, and a shared purpose towards the trial's goals. * **Beyond Basic eTMF Compliance:** A "fourth-generation eTMF" goes beyond fundamental capabilities like 21 CFR Part 11 compliance, missing document tracking, version control, access management, and e-signatures. It must support advanced features for true collaboration. * **Features of a Modern eTMF:** Essential features for effective collaboration include connecting investigator sites with their own eISF workspaces, enabling remote monitoring capabilities, facilitating collaborative authoring of documents, supporting robust review and approval workflows, allowing for task assignments (e.g., from monitor to site), and providing comprehensive dashboards for real-time tracking and metrics. * **Integration of eISF:** The electronic Investigator Site File (eISF) is critical for empowering sites to manage their essential documents while providing CROs and sponsors with secure, controlled access for remote monitoring, review, and seamless transfer of approved documents into the central eTMF. * **ClinOps Technology Adoption Curve:** Organizations can assess their technology maturity in clinical operations using a five-stage curve: 1) Basic Tools (spreadsheets, shared folders), 2) Core Systems (eTMF, CTMS, EDC), 3) Automated/Interactive Processes, 4) Connected Systems, and 5) Fully Digitized Nirvana. Strategic technology investments should aim to move companies up this curve. * **Impact on Quality and Efficiency:** Implementing an advanced eTMF system significantly contributes to improved trial quality by capturing all interactions, reducing human errors, streamlining processes, and enhancing visibility and accountability across the trial. * **Regulatory Scrutiny and Access:** The FDA is increasingly asking for direct access to eTMFs for audits, emphasizing the need for systems that are not only compliant but also intuitive and comprehensive enough to stand alone in telling the trial's story without extensive verbal explanation. * **Post-Study TMF Archiving:** Modern eTMF systems allow for easy export of the entire TMF (e.g., as a structured zip file with PDFs) for long-term archiving or transfer to a sponsor's document management system. Incremental transfers are possible, though full real-time synchronization between disparate systems is often complex and costly. * **Importance of Early Rapport:** Investing time in building rapport and trust during initial interactions, such as kickoff meetings, is crucial. This foundational trust makes it significantly easier to navigate inevitable challenges and difficult conversations later in the trial. * **CRO as a Technology Partner:** Mid-sized CROs like DZS Clinical Services often act as technology advisors for smaller sponsors, recommending robust, intuitive, dynamic, and cost-effective eTMF solutions that align with the client's needs and budget. **Tools/Resources Mentioned:** * **Agatha eTMF:** The featured electronic Trial Master File software. * **Inbox/Dropbox:** Mentioned as less ideal, uncontrolled alternatives for document management. * **Documentum, OpenText, Filenet:** Examples of traditional document management systems (DMS) that might receive exported TMFs. * **White Paper/E-book:** "How CROs and Sponsors can leverage an eTMF for Collaboration" (co-authored by the speakers and others). * **ClinOps Technology Adoption Curve Audit:** An offer for a free audit and report by Ken Lownie to assess a company's technology maturity and recommend investments. **Key Concepts:** * **Trial Master File (TMF):** The collection of essential documents that individually and collectively permit the evaluation of the conduct of a clinical trial and the quality of the data produced. * **Electronic Trial Master File (eTMF):** A TMF maintained in electronic format, typically within a specialized software application designed to ensure compliance with regulatory requirements (e.g., 21 CFR Part 11). * **Investigator Site File (ISF):** The collection of essential documents maintained at the clinical trial site by the investigator. * **Electronic Investigator Site File (eISF):** An ISF maintained in electronic format, often integrated or connected with the eTMF for remote monitoring and oversight. * **21 CFR Part 11:** Regulations issued by the FDA that set forth the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. * **GxP:** A collection of quality guidelines and regulations for good practices in various regulated fields, including Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Laboratory Practice (GLP). * **ClinOps Technology Adoption Curve:** A conceptual framework illustrating the stages of technology integration and maturity within clinical operations, from basic tools to fully digitized and automated processes.
Self-Funded w/ Spencer - Mike Kohl - Episode 36
Self-Funded
@SelfFunded
Feb 15, 2022
This video provides an in-depth exploration of "next generation wellness" and "whole person healthcare" within the context of employer-sponsored health plans. Featuring Mike Kohl, VP of Sales for Vida Health, the discussion, hosted by Spencer, delves into the evolution of wellness programs and the critical need for integrated mental and physical health support to address chronic conditions and rising healthcare costs. Kohl, drawing from his 30 years of experience in the insurance industry, offers a seasoned perspective on the complexities of self-funding and the strategic shift towards more effective member engagement strategies. A central theme of the conversation is Vida Health's "whole health perspective," which posits that physical chronic conditions, such as diabetes, are frequently intertwined with mental health issues like stress, anxiety, and depression in approximately 70% of cases. Kohl emphasizes that merely treating the physical aspect provides only "half a solution," as true and sustainable health improvement necessitates addressing the underlying behavioral and emotional drivers. This integrated approach aims to guide individuals from an unhealthy to a healthy lifestyle by tackling the root causes of their health challenges, rather than just managing symptoms. Vida Health's methodology involves an app-based enrollment process where members undergo initial assessments using PHQ and GAD scores to establish a baseline for stress and depression levels. Following this, members are empowered to choose a personalized coach from a diverse pool, including health coaches, psychologists, pharmacists, or licensed clinical managers, and then engage in a structured cognitive behavioral therapy pathway. A crucial aspect of their strategy is "meeting the member where they are," offering flexible communication channels such as text and asynchronous discussions to overcome initial resistance and cater to individual preferences and schedules. The company also strategically leverages claims data and advanced analytics to proactively identify and outreach to high-priority members, ensuring timely and targeted interventions. The discussion highlights the significant impact of this integrated approach, with Vida Health reporting substantial "15 or 16 claim savings" for employers by effectively managing both mental and physical health. A critical societal problem addressed is the severe shortage of mental health providers in the United States, with only about 27% capacity available, leading to lengthy wait times for care. Vida Health aims to bridge this accessibility gap by providing immediate access to support, often within 24 hours, thereby diminishing the timeframe for individuals to receive necessary care and achieve a better overall health state. Key Takeaways: * **Evolution of Wellness Programs:** Traditional wellness initiatives, such as providing pedometers or promoting healthy eating with superficial incentives, often lacked the deep member engagement required for long-term effectiveness, necessitating a shift towards more integrated and data-driven approaches. * **Interconnectedness of Health:** Effective health management must recognize and treat the profound interconnectedness of physical and mental well-being; chronic physical conditions are frequently co-morbid with mental health issues, with approximately 70% of individuals with diabetes also experiencing related mental health challenges. * **Addressing Underlying Behavioral Drivers:** Sustainable health improvement goes beyond symptom management, requiring a deeper understanding and intervention into the behavioral, emotional, and psychological factors that drive unhealthy choices and contribute to chronic conditions. * **Personalized Coaching and CBT:** Tailoring support through member-chosen coaches (e.g., health coaches, psychologists) and structured cognitive behavioral therapy (CBT) pathways significantly enhances member engagement, adherence to treatment plans, and overall health outcomes. * **Flexible Engagement Models for Participation:** Overcoming member resistance and increasing participation rates in wellness programs demands meeting individuals "where they are" through flexible communication channels like text and app-based interactions, allowing for asynchronous discussions and engagement at their own pace. * **Data-Driven Member Identification:** Utilizing claims data and advanced analytics is crucial for proactively identifying high-priority members who would benefit most from early intervention, enabling targeted marketing and engagement strategies to optimize resource allocation. * **Immediacy of Mental Health Care:** The severe shortage of mental health providers in the US (only 27% capacity) underscores the critical need for virtual solutions that offer immediate access to care, reducing prohibitive wait times and providing support during crucial emotional moments. * **Significant Financial Impact:** An integrated approach to mental and physical health can lead to substantial cost savings for employer-sponsored health plans, with reported figures indicating "15 or 16 claim savings" by improving overall member health and reducing high-cost claims. * **Complexity of Self-Funded Plans:** Self-funded health plans, while offering significant control and flexibility to employers, are inherently complex and require deep expertise from consultants and brokers to navigate effectively and maximize their financial and operational benefits. * **Importance of Continuous Professional Education:** The dynamic healthcare and insurance industries necessitate continuous education and professional designations (like CEBS or CSFS) to maintain credibility, expand specialized knowledge, and differentiate expertise in a rapidly evolving landscape. * **Lifestyle as a Foundation for Health:** Personal choices regarding exercise, diet, and stress management form the foundational elements of physical and emotional well-being, highlighting the importance of fostering healthier lifestyles to prevent the onset and progression of chronic diseases. * **Technology as a Healthcare Enabler:** Technology, through app-based platforms and specialized "point solutions," is revolutionizing healthcare delivery by enabling personalized, accessible, and data-driven approaches to wellness and chronic disease management. **Key Concepts:** * **Whole Person Healthcare:** An integrated approach to health that recognizes and treats the interconnectedness of an individual's physical and mental well-being, addressing both simultaneously for comprehensive improvement. * **Cognitive Behavioral Therapy (CBT):** A common type of talk therapy that helps people identify and change destructive or disturbing thought patterns that have a negative influence on behavior and emotions. * **PHQ (Patient Health Questionnaire) & GAD (Generalized Anxiety Disorder) Scores:** Standardized screening tools used to assess the severity of depression (PHQ) and anxiety (GAD) symptoms, providing a baseline for mental health status. * **Self-Funded Health Plan:** An employer-sponsored health plan where the employer directly pays for employees' medical claims rather than paying a fixed premium to an insurance carrier. This offers greater control and potential cost savings but also higher risk. * **Point Solutions:** Specialized, often technology-driven, healthcare services or products designed to address a specific health condition or need (e.g., a diabetes management app, a mental health coaching platform). **Examples/Case Studies:** * **Vida Health's Origin Story:** The company was founded by Stephanie Telenius, whose personal struggle navigating the complex healthcare system for her father's chronic physical and mental conditions highlighted the critical need for a more integrated and user-friendly approach to care. * **Diabetes and Mental Health Co-morbidity:** The statistic that approximately 70% of individuals with diabetes also experience co-occurring mental health issues (stress, anxiety, depression) serves as a compelling example of why a whole-person approach is essential for effective chronic disease management. * **Mental Health Provider Accessibility Crisis:** The alarming statistic that only about 27% of the US population can access reasonable care from a psychologist, leading to significant wait times (e.g., 30 days), illustrates the critical accessibility challenge that virtual health solutions like Vida Health aim to solve by providing immediate support.
Doctor Pay: RVUs Determine Income
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Feb 13, 2022
This video, presented by Dr. Eric Bricker of AHealthcareZ, provides an in-depth explanation of how physician compensation in the United States is largely determined by Work Relative Value Units (wRVUs). Building on a previous discussion about physician payment, Dr. Bricker clarifies that wRVUs are standardized units tied to specific Current Procedural Terminology (CPT) codes, which doctors use to bill for their services. These codes cover a range of activities from evaluation and management (E&M) office visits to complex surgical procedures, with the wRVU value reflecting the relative time, effort, and skill required for each service. Dr. Bricker illustrates this system with concrete examples, noting that a 20-minute new patient office visit (CPT 99202) typically yields 0.93 wRVUs, while a colonoscopy with biopsy (CPT 45380) generates a significantly higher 3.56 wRVUs. He then translates these units into annual income, demonstrating that a gastroenterologist billing 10,500 wRVUs per year (placing them in the 75th percentile) could earn approximately $712,000, based on an average reimbursement of $68 per wRVU. This direct correlation between wRVU volume and income forms the bedrock of physician payment in a fee-for-service environment. A central theme of the video is the stark disparity in wRVU generation across medical specialties. Dr. Bricker presents median annual wRVU data, showing that high-procedure specialties like cardiothoracic surgery (9,822 wRVUs), neurosurgery (9,333 wRVUs), and radiology (8,862 wRVUs) far outpace primary care physicians (PCPs) in internal medicine and family practice, who average only 4,900 wRVUs per year. This significant difference exists despite specialists and PCPs working nearly the same number of hours per week (52 vs. 51 hours, respectively). The speaker argues that this discrepancy stems from the fact that much of the essential care coordination work performed by PCPs—such as phone calls, emails, medical record management, and family conversations—is not reimbursable through existing CPT codes, and thus does not generate wRVUs. The video critically examines the benefits and pitfalls of the wRVU system. For employers (hospital systems, private equity firms), the system is advantageous as it incentivizes doctors to see more patients and perform more procedures, keeping facilities busy and driving volume. However, for physicians, particularly PCPs, a major drawback is that they are not compensated for all the work they do, leading to a system that prioritizes volume over quality. Dr. Bricker highlights that while Medicare introduced CPT code 99490 in 2015 for chronic care management and coordination, commercial insurance companies largely do not reimburse for it. This lack of reimbursement for crucial care coordination activities, he concludes, is a fundamental flaw that inherently hampers adequate and effective primary care, suggesting that meaningful primary care reform will remain elusive until this payment structure is addressed. Key Takeaways: * **Work Relative Value Units (wRVUs) are the primary determinant of physician income in the fee-for-service model.** These units are assigned to specific Current Procedural Terminology (CPT) codes, reflecting the relative time, effort, and skill involved in a medical service. * **CPT codes translate directly into wRVUs, which then translate into physician compensation.** For example, a 20-minute new patient office visit (CPT 99202) yields 0.93 wRVUs, while a colonoscopy with biopsy (CPT 45380) yields 3.56 wRVUs, demonstrating how procedural work often generates higher units. * **Physician income is directly proportional to the volume of wRVUs billed.** A gastroenterologist in the 75th percentile, billing 10,500 wRVUs annually, is estimated to earn approximately $712,000, based on an average rate of $68 per wRVU. * **There is a significant disparity in wRVU generation between specialists and primary care physicians (PCPs).** High-procedure specialties like cardiothoracic surgery and neurosurgery generate nearly double the wRVUs (e.g., 9,822 and 9,333 respectively) compared to PCPs (e.g., 4,900). * **This wRVU disparity exists despite specialists and PCPs working comparable hours per week.** Surveys indicate specialists work an average of 52 hours per week, while PCPs work 51 hours, highlighting that the issue is not workload but rather billable work. * **The primary reason for lower PCP wRVUs is the lack of reimbursement for extensive care coordination activities.** PCPs spend significant time on phone calls, emails, medical record management, and family conversations that are not tied to specific, reimbursable CPT codes. * **Medicare introduced CPT code 99490 in 2015 to compensate for chronic care management and coordination, but commercial insurance largely does not reimburse for it.** This creates a critical gap where essential primary care services go unpaid, impacting the quality and availability of coordinated care. * **The wRVU-based system primarily benefits employers (hospital systems, private equity firms) by incentivizing volume.** Doctors compete for patients and procedures to maximize wRVUs, keeping facilities busy, but this can lead to over-utilization of services. * **A major pitfall for physicians under the wRVU system is that they are not paid for all the work they do.** This is particularly acute for PCPs, where a substantial portion of their effort in care coordination remains uncompensated. * **The current payment model incentivizes volume over quality.** Physicians are paid based on the number of services rendered (wRVUs), not on patient outcomes or the quality of care provided, which can misalign incentives with patient well-being. * **The "what you pay for gets done" principle is a critical factor in healthcare delivery.** When care coordination is not reimbursed by commercial insurers, it often means that the necessary level of coordination for patients is not provided, leading to fragmented care. * **The existing wRVU-based fee-for-service system inherently hampers adequate and effective primary care.** Until this payment structure is reformed to properly compensate for comprehensive primary care activities, achieving robust primary care will remain a significant challenge. Key Concepts: * **Work Relative Value Units (wRVUs):** A standardized measure of the physician's work (time, effort, skill, and intensity) associated with providing a service. They are a key component in determining physician compensation, particularly in fee-for-service models. * **Current Procedural Terminology (CPT) Codes:** A set of medical codes used by physicians, hospitals, and other healthcare providers to describe the services they provide to patients. These codes are used for billing and reimbursement purposes. * **RUC (Relative Value Scale Update Committee):** A committee of the American Medical Association that makes recommendations to Medicare on the relative values (including wRVUs) assigned to CPT codes. * **Evaluation and Management (E&M) Codes:** A subset of CPT codes used to bill for physician services related to patient evaluation and management, such as office visits, hospital visits, and consultations. * **Care Coordination (CPT 99490):** A specific CPT code introduced by Medicare in 2015 for chronic care management services, allowing primary care physicians to bill for at least 20 minutes of non-face-to-face care coordination activities per month for patients with multiple chronic conditions. Examples/Case Studies: * **CPT Code 99202 (New Patient Office Visit):** Described as a medium-to-lower complexity visit, typically involving 20 minutes of face-to-face time, assigned 0.93 wRVUs. * **CPT Code 45380 (Colonoscopy with Biopsy):** A procedural code typically performed by a gastroenterologist, taking 30-60 minutes, assigned 3.56 wRVUs. This illustrates how procedural codes generally carry higher wRVU values than E&M codes. * **Gastroenterologist Compensation Example:** A gastroenterologist billing 10,500 wRVUs annually (75th percentile) is estimated to earn approximately $712,000, based on an average rate of $68 per wRVU. * **Specialty wRVU Disparity:** * Cardiothoracic Surgeons: 9,822 wRVUs/year * Neurosurgeons: 9,333 wRVUs/year * Radiologists: 8,862 wRVUs/year * Ophthalmologists: 8,438 wRVUs/year * Orthopedic Surgeons: 8,009 wRVUs/year * Primary Care Physicians (Internal Medicine/Family Practice): 4,900 wRVUs/year This stark contrast highlights the systemic undervaluation of primary care within the wRVU framework, despite similar work hours compared to specialists.
Trial Master File Career Growth: What are my options?
Nicole Palmer
/@granularlevel
Feb 10, 2022
This video provides an in-depth exploration of career growth opportunities within the Trial Master File (TMF) industry, guiding individuals on potential paths after gaining experience in TMF-related roles. The speaker, Nicole Palmer, frames the discussion around a fundamental question: whether an individual prefers managing "people" or "processes," asserting that this preference is a key determinant for career direction. This framework helps segment various roles within clinical operations and related fields, illustrating how different inclinations can lead to distinct specializations and upward mobility. The discussion begins by positioning the Clinical Trial Assistant (CTA) role as an excellent starting point for those who enjoy the TMF aspect of clinical trials. The CTA is described as a central liaison, facilitating communication among various study stakeholders including the study coordinator, project manager, CRA (Clinical Research Associate), and sponsor. This initial role offers broad exposure to the entire study lifecycle, providing a foundational understanding of clinical trial dynamics. From this base, the video outlines several progression paths, such as advancing to a Senior CTA and potentially managing CTA departments for those inclined towards people management. For individuals who gravitate towards specific processes, the video highlights roles like a Study Startup Specialist, focusing on the intricate process of getting clinical sites operational, involving close collaboration with contracts and budgets personnel, sites, and project managers. Another process-oriented path from a CTA background is moving into a Junior CRA or In-house CRA role, with the option to become a Traveling CRA for those who enjoy travel. The speaker also suggests that a preference for processes could lead to a career in Quality Assurance (QA), involving the writing of Standard Operating Procedures (SOPs) and conducting or responding to audits. Alternatively, a completely different, data-focused route is presented through becoming a Clinical Data Liaison (CDL), with potential advancement to Senior CDL and managing data departments. The overarching message is that the industry offers diverse and extensive opportunities, contingent on one's core interest in managing either people or processes. Key Takeaways: * **Fundamental Career Differentiator:** The primary determinant for career progression in the TMF and clinical trial industry is an individual's preference for managing "people" versus "processes." This distinction helps align personal strengths and interests with suitable professional roles. * **Clinical Trial Assistant (CTA) as a Foundational Role:** Starting as a CTA provides comprehensive exposure to clinical study operations, acting as a crucial communication liaison between various stakeholders such as study coordinators, project managers, CRAs, and sponsors. This role offers a holistic view of the study lifecycle. * **Progression within People Management:** For those who enjoy managing people, a CTA can advance to a Senior CTA and eventually manage CTA departments, overseeing teams and coordinating efforts within clinical operations. * **Study Startup Specialization:** Individuals passionate about the initial phases of clinical trials can pursue a career as a Study Startup Specialist, focusing on activating sites, managing contracts and budgets, and collaborating closely with project managers to ensure efficient study initiation. This role demands excellent customer service skills. * **Clinical Research Associate (CRA) Paths:** A CTA with a year of experience can transition into a Junior CRA or In-house CRA role. For those willing to travel extensively, becoming a Traveling CRA offers a dynamic career path focused on monitoring clinical sites. * **Project Management for People-Oriented Individuals:** Aspiring project managers can leverage their experience in clinical operations and a preference for managing people to move into Project Manager roles, overseeing entire clinical trials and coordinating diverse teams. * **Quality Assurance (QA) for Process Enthusiasts:** Individuals who enjoy meticulous processes, writing documentation, and ensuring compliance can pursue a career in Quality Assurance, focusing on developing SOPs, conducting audits, and managing audit responses. This area is critical for regulatory adherence. * **Clinical Data Liaison (CDL) for Data-Focused Careers:** A distinct path is available in data management, starting as a Clinical Data Liaison. This role focuses on managing clinical data, with opportunities to advance to Senior CDL and ultimately manage entire data departments. * **Interconnectedness of Roles:** The video implicitly highlights the collaborative nature of clinical trials, where roles like CTA, CRA, Project Manager, and Study Startup Specialist work in concert, emphasizing the importance of understanding various functions within the ecosystem. * **Endless Options Based on Preference:** The speaker concludes that once an individual identifies their core preference (people vs. processes), the career options within the clinical trial and TMF industry are "endless," indicating a broad spectrum of specialization and growth opportunities. Key Concepts: * **Trial Master File (TMF):** A collection of essential documents for a clinical trial that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate compliance with Good Clinical Practice (GCP) and regulatory requirements. * **Clinical Trial Assistant (CTA):** An entry-level role in clinical research, often responsible for administrative support, document management (including TMF), and communication coordination within a clinical study. * **Clinical Research Associate (CRA):** A professional who monitors clinical trials, ensuring compliance with the study protocol, GCP, and regulatory requirements. CRAs can be in-house or travel to investigator sites. * **Study Startup Specialist:** A role focused on the initial phase of a clinical trial, responsible for activities like site selection, contract negotiation, budget finalization, and regulatory document collection to activate study sites. * **Quality Assurance (QA):** A department or function responsible for ensuring that all aspects of a clinical trial comply with regulatory requirements, internal policies, and quality standards, often involving SOP development and audits. * **Standard Operating Procedures (SOPs):** Detailed, written instructions to achieve uniformity of the performance of a specific function. They are critical for maintaining quality and regulatory compliance in clinical research. * **Clinical Data Liaison (CDL):** A role focused on the management, collection, and quality control of clinical trial data, often serving as a bridge between clinical operations and data management teams.
Future of eTMF Document Reviewer Career
Nicole Palmer
/@granularlevel
Feb 8, 2022
This video provides a concise yet impactful perspective on the career trajectory and significance of an eTMF (electronic Trial Master File) document reviewer within the pharmaceutical and life sciences industries. The speaker, Nicole Palmer, addresses a direct question from a current eTMF document reviewer, offering strong encouragement and strategic advice regarding the future of this specialized role. The core message revolves around the immense value and foundational nature of eTMF experience in today's clinical research landscape. Palmer emphasizes that experience in eTMF is "gold," positioning it as a highly sought-after skill in an industry rapidly moving away from traditional paper-based processes. She explicitly states that "paper TMFs are a thing of the past," underscoring the irreversible shift towards digital solutions for managing clinical trial documentation. This transition makes professionals proficient in eTMF systems indispensable, as they are at the forefront of ensuring data integrity, regulatory compliance, and operational efficiency in clinical trials. The video further highlights that working in eTMF provides a robust foundation for a diverse range of career advancements. Whether an individual wishes to specialize further within eTMF or transition into broader roles such as project management, Clinical Research Associate (CRA), or Quality Assurance (QA), the foundational knowledge gained from eTMF document review is presented as a critical stepping stone. The speaker's advice is clear: stay committed to the eTMF domain, continuously learn, and leverage this expertise as a springboard for future professional growth, whether within the eTMF specialization or in related clinical operations roles. Key Takeaways: * **eTMF Experience is Highly Valued:** The video unequivocally states that experience in electronic Trial Master File (eTMF) is "gold," signifying its critical importance and high demand within the pharmaceutical and life sciences sectors. This is due to the regulatory necessity of maintaining accurate and complete clinical trial documentation. * **Shift from Paper to Digital is Permanent:** The era of paper-based Trial Master Files is over. The industry has fully transitioned to eTMFs, making expertise in these digital systems essential for any organization involved in clinical research. Companies must embrace digital solutions for efficiency and compliance. * **Foundational Career Path:** Working as an eTMF document reviewer provides a strong foundational understanding of clinical trial processes, regulatory requirements, and document management. This knowledge serves as an excellent base for various career advancements within clinical operations. * **Versatile Career Progression:** Professionals with eTMF experience are well-positioned for upward mobility. This includes specializing further within eTMF management or transitioning into roles like Clinical Project Manager, Clinical Research Associate (CRA), or Quality Assurance (QA) specialist, leveraging their deep understanding of trial documentation. * **Continuous Learning is Crucial:** The speaker advises individuals to "learn as much as you possibly can" while in an eTMF role. Given the evolving nature of technology and regulations, continuous professional development in eTMF systems, best practices, and compliance standards is vital for long-term success. * **Strategic Career Decision:** Individuals passionate about eTMF should consider specializing and growing within this domain. For those seeking broader roles, eTMF experience acts as a strategic launchpad, providing credibility and a comprehensive understanding of clinical trial data flow. * **Regulatory Compliance Expertise:** eTMF document reviewers inherently develop expertise in regulatory compliance (e.g., FDA, EMA, GxP, 21 CFR Part 11) as they ensure all trial documents meet stringent standards. This makes them invaluable assets in maintaining audit readiness and data integrity. * **Data Integrity and Quality Assurance:** The role of an eTMF document reviewer is central to ensuring the quality, accuracy, and completeness of clinical trial data. Their work directly contributes to the reliability of trial results and the overall integrity of the clinical development process. Key Concepts: * **eTMF (electronic Trial Master File):** The eTMF is a comprehensive collection of essential documents for a clinical trial, maintained in an electronic format. These documents collectively demonstrate the conduct of a trial, the integrity of the data, and the compliance of the trial with Good Clinical Practice (GCP) and applicable regulatory requirements. It is a critical component for regulatory inspections and audits. * **GxP (Good Practice):** A set of guidelines and regulations that ensure the quality, safety, and efficacy of products in the life sciences industry. This includes Good Clinical Practice (GCP) for clinical trials, Good Manufacturing Practice (GMP) for manufacturing, and Good Laboratory Practice (GLP) for laboratory studies. * **21 CFR Part 11:** A regulation issued by the U.S. Food and Drug Administration (FDA) that sets forth criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. This is crucial for the validity of eTMF systems. Examples/Case Studies: While the video does not provide specific examples or case studies, the implications of its message are clear for companies like IntuitionLabs.ai. The emphasis on eTMF's "gold" status and the shift from paper highlights the ongoing need for: * **Advanced eTMF System Integration:** Companies require robust solutions to integrate eTMF systems with other clinical trial management systems (CTMS), regulatory information management systems (RIMS), and quality management systems (QMS). * **AI-Powered Document Review and Compliance:** The labor-intensive nature of eTMF document review presents a prime opportunity for AI and LLM solutions. AI can automate initial document classification, metadata extraction, compliance checks against regulatory guidelines, and identification of missing or inconsistent documents, significantly enhancing efficiency and accuracy. * **Data Engineering for eTMF Analytics:** Building data pipelines and business intelligence dashboards around eTMF data can provide actionable insights into trial progress, document completeness, and potential compliance risks, allowing for proactive management. * **Veeva CRM and Vault Integration:** For companies utilizing Veeva Vault eTMF, specialized consulting services are essential for optimal implementation, customization, and integration, ensuring that the system meets specific operational and regulatory needs.
How Are Doctors Paid? Learn the Incentives in Physician Compensation
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Feb 5, 2022
This video provides an in-depth exploration of physician compensation models, specifically highlighting the pervasive dominance of volume-based incentives over value-based care within hospital-owned physician practices in the United States. Dr. Eric Bricker, of AHealthcareZ, presents findings from a recent RAND and Harvard University study published in the Journal of the American Medical Association (JAMA), which critically examines how doctors are paid and the implications for healthcare innovation and patient care. The core argument is that despite widespread rhetoric and efforts by government and insurance payers to implement value-based reimbursement models for hospitals, these incentives often fail to trickle down to the individual physician level, creating a significant disconnect. The presentation details the study's findings, which analyzed 31 physician practices owned by 22 different hospital systems. The research revealed that a vast majority of primary care physicians (84%) and specialists (93%) were compensated primarily based on the volume of patients seen and services rendered, measured by Relative Value Units (RVUs). In stark contrast, only a meager 9% of primary care physician compensation and 5.3% of specialist compensation was tied to quality and cost-effectiveness metrics. This demonstrates that while hospitals may receive value-based payments from external payers, their internal compensation structures for employed physicians remain heavily skewed towards maximizing volume and, consequently, health system revenue, rather than promoting patient outcomes or cost efficiency. Dr. Bricker emphasizes that this "window dressing" approach to value-based care at the payer-hospital level has profound implications for the doctor-patient relationship. He argues that as long as physicians are incentivized for "doing stuff" (fee-for-service) rather than for achieving positive outcomes or being cost-effective, their clinical decisions will inherently be influenced by volume targets. This systemic issue, as articulated by an anonymous leader from a hospital-owned physician practice quoted in "The Gist" newsletter, actively limits the ability to innovate and consistently pressures practices to maximize specialist referrals, often at the expense of other patient-centric goals. The video concludes by advocating for the importance of independent physician practices as a potential counter-model, suggesting that independence might foster environments more conducive to value-based care, though not guaranteeing it. Key Takeaways: * **Dominance of Volume-Based Pay:** A recent RAND and Harvard study found that 84% of primary care physicians and 93% of specialists in hospital-owned practices are paid based on patient volume and services (fee-for-service), not on quality or cost-effectiveness. This means doctors are incentivized for "doing stuff" rather than achieving specific patient outcomes. * **Minimal Value-Based Compensation:** Only 9% of primary care physician compensation and a mere 5.3% of specialist compensation was linked to value-based metrics (quality and cost-effectiveness), indicating a significant gap between stated goals and actual physician incentives. * **"Window Dressing" of Value-Based Care:** Despite federal government and insurance carriers pushing "payment innovation" and value-based reimbursement models to hospitals, these incentives often do not translate to how hospitals compensate their employed physicians. The internal compensation structure remains volume-based, effectively blocking the intended shift towards value at the point of care. * **Maximizing Health System Revenue:** Physician compensation within hospital systems is largely dominated by volume-based incentives explicitly designed to maximize health system revenue, as concluded by the JAMA study. This financial imperative often overrides broader goals of quality and cost-effectiveness. * **Disconnect in Incentives:** There is a critical disconnect between how payers reimburse hospitals (increasingly value-based) and how hospitals, in turn, pay their doctors (still predominantly volume-based). This creates a system where the doctor-patient relationship remains largely within a fee-for-service environment, despite external pressures for change. * **Impact on Innovation and Referrals:** The volume-based incentive structure limits innovation within physician practices and creates pressure to maximize specialist referrals over other goals, potentially impacting patient care pathways and overall healthcare costs. * **Importance of Observing Actions, Not Just Words:** The video emphasizes Andrew Carnegie's quote: "Don't listen to what people say, but watch what they do." In healthcare, this means observing how physicians are actually paid, not just listening to rhetoric about value-based care initiatives. * **Role of Independent Practices:** Approximately 50% of doctors in America still work in independent physician practices. The speaker suggests that independent practices, by not being tied to hospital systems' revenue maximization goals, may offer a more conducive environment for implementing true value-based care, though this is not a guarantee. * **RVUs as a Key Metric:** Relative Value Units (RVUs) are the primary metric used within hospital systems to measure the volume of services provided by physicians, directly linking compensation to the quantity of work performed. * **Implications for Patient Care Decisions:** The prevailing fee-for-service model means that doctors are incentivized to perform more services, which can influence diagnostic and treatment decisions, potentially leading to over-utilization rather than focusing on the most cost-effective or highest-quality care. Tools/Resources Mentioned: * **Journal of the American Medical Association (JAMA):** A preeminent medical journal that published the RAND/Harvard study discussed in the video. * **RAND Corporation:** A very famous research and development think tank that co-authored the study. * **Harvard University:** Co-authored the study on physician compensation. * **The Gist Newsletter:** A fantastic newsletter mentioned by Dr. Bricker, which provided an anonymous quote from a physician practice leader. Key Concepts: * **Value-Based Care/Reimbursement:** A healthcare payment model that rewards providers for the quality of care they deliver, rather than the quantity of services. It aims to improve patient outcomes and reduce costs. * **Fee-for-Service (FFS):** A traditional payment model where healthcare providers are paid for each service they perform (e.g., office visit, test, procedure). This model incentivizes volume. * **Relative Value Units (RVUs):** A measure of the value of a physician's work, used in the fee-for-service system. RVUs consider the physician's work, practice expense, and malpractice expense, and are used to determine physician compensation. * **Payment Innovation/Alternative Payment Models (APMs):** Initiatives by government and insurance carriers to move away from traditional fee-for-service models towards value-based care. * **Hospital System-Owned Practices:** Physician practices that are directly employed by or affiliated with hospital systems, representing about 50% of doctors in the U.S. Examples/Case Studies: * **RAND and Harvard University Study (Published in JAMA, January 28, 2022):** The central example, this cross-sectional study examined 31 physician practices owned by 22 different hospital systems to analyze physician compensation structures. Its key finding was the overwhelming dominance of volume-based incentives for both primary care physicians and specialists. * **Anonymous Quote from a Physician Practice Leader (from The Gist newsletter):** A real-world perspective from a leader within a hospital-owned physician group, acknowledging that the pressure to maximize specialist referrals is always present and "undoubtedly limits our ability to innovate." This quote corroborates the study's findings about the internal focus on revenue maximization.